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ABSTRACT 
Background &Objectives:  Gastric cancer is one of the leading causes of death and the 
fourth most prevalent cancer in the world. Most cases of gastric carcinoma are detected in 
advanced stages and are associated with high mortality and bad prognosis. For such 
advanced diseases, treatment options are limited. Trastuzumab   has been approved for 
metastatic or locally advanced carcinomas arising in the stomach or the gastro esophageal 
junction in patients with HER2-positive tumours.  The multicentre TOGA trial proved 
that targeted therapy could prolong patient lives by 2.7 months when compared to the 
standard treatment. There is limited data on the prevalence and behavior of HER2-
positive cases among Indian patients.  The current study aims to, 
1.  Compare HER2 expression between matched diagnostic biopsies and surgical 
specimens of patients with gastric adenocarcinoma in India. 
2. Correlate HER 2 expression with important prognostic pathological parameters and to 
determine the effect of non-Trastuzumab containing neo adjuvant chemotherapy (NAC) 
on this expression. 
3. To study tumour heterogeneity among the HER2 positive Gastric adenocarcinomas  
Type of study: prospective observational study. 
Materials and Methods:  Matched primary gastrectomy sections with corresponding 
diagnostic biopsies of 72 patients reported from June 1, 2016, to July 30, 2017 were used 
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from the archives of the Department of Pathology.  The immunohistochemical study was 
conducted using MILD CC 1 protocol  perform with anti-HER 2/neu (4B5) Rabbit 
Monoclonal Primary Antibody, and the Ventana Pathway using automated slide stainer 
Ventana Bench mark XT.  We stained whole-tissue sections with their matching 
diagnostic mucosal biopsies on the same slide. We comparedHER2expression status with 
all pathological parameters to assess statistically significant associations by the Chi-
square test. HER-2 overexpression (HER2+) was deﬁned by a score 3+ on IHC  
according to the standardized and validated scoring system of Hoffmann et al. used in 
most international trials including the TOGA trial. 
Results:  Paired HER2 status was determined for 72 patients (100%). HER2+ rates were 
8.33% on biopsy (6/72) and 9.72% on resection (7/72). The overall HER2 positivity rate 
was 11.11% (8/72). There was an association between HER2 expression and WHO 
mixed   adeno carcinoma histological subtype (P = 0.009) and presence of 
lymphovascular invasion (P = 0.045). No association was found between HER2 status 
and all other pathological parameters. When we independently analyzed the cases, 14/ 58 
cases were NAC treated cases, and 3 cases showed HER 2 positivity. In non-NAC 
patients 4/5 (80%) HER 2 positive cases showed concordance between the biopsy and 
resection. The remaining 1/5 case showed discordance with a positive shift. In the NAC 
group 3/3 (100%) HER 2 positive cases showed discordance with 2/3showing negative 
shift and 1/3 with the positive shift.  All 3/5 (60%) treated patients showed tumour 
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heterogeneity and all three were mixed type. The remaining 2/5(40%) showed 
homogeneous staining pattern and were of the WHO tubular variant 
Conclusion: To our best knowledge this is the first study to analyse HER 2 expression in 
72 matched biopsies with the corresponding resections in India and this largest study 
group compared with other similar studies published in India. Differences between 
biopsy and resection HER2 expression could be explained by intratumoral heterogeneity 
and by decreased HER2 expression in surgical sections after NAC in responding patients 
possibly due to a higher chemo sensitivity of HER2-positive clones. Combining the 
analysis of biopsy and resections could optimize the selection of Trastuzumab-eligible 
patients in case of advanced gastric adenocarcinoma particularly in previously NAC-
responding patients having a mixed histological type of tumour with lymphovascular 
invasion. 
Keywords: Her2, gastric cancer, neoadjuvant chemotherapy, Immunohistochemistry. 
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ABBREVIATIONS 
CISH: CHROMOGENIC IN SITU HYBRIDIZATION 
ELISA: ENZYME LINKED   IMMUNOSORBENT ASSAY 
FISH: FLUORESCENCE IN SITU HYBRIDIZATION 
GEJ: GASTROESOPHAGEAL JUNCTION 
H.PYLORI: HELICOBACTER PYLORI 
HER2: HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 
IHC: IMMUNOHISTOCHEMISTRY. 
NACT:  NEOADJUVENT CHEMOTHERAPY 
TOGA: TRASTUZUMAB FOR GASTRIC CANCER TRIAL 
WHO:  WORLD HEALTH ORGANISATION. 
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INTRODUCTION 
 
 
Gastric carcinoma is one of the most common tumours that cause death globally and most 
cases are diagnosed only in very late stages are associates with a high incidence of 
tumour metastasis. For such cases, the scope of surgical resection is restricted. 
Trastuzumab is a monoclonal antibody used in the management of tumours which 
interferes with HER 2 receptor function and increases overall survival.  Our current study 
correlated the immunohistochemical (IHC) expression of HER 2 with variables such as 
tumour classifications, tumour topography, tumour grading and TNM stage in matched 
mucosal biopsies and gastric resection specimens of the patients with adenocarcinoma. 
The primary objective of our study was to analyse the prevalence of HER 2 expression in 
gastric carcinoma in our hospital and nature of tumorogenesis including tumour 
heterogeneity. Cases were recruited from 1 June 2016 to 30 July 2017. 
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AIM & OBJECTIVES 
 
 
 Study the HER 2 over expression by immunohistochemistry in gastric 
adenocarcinoma patients diagnosed in our hospital. 
 
 Correlate the expression of HER 2 by immunohistochemistry in gastric carcinoma 
with pathological parameters 
 
 Correlate the expression of HER 2 in mucosal biopsies and surgical resections of 
the same patients. 
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REVIEW OF LITERATURE 
 
EPIDEMIOLOGY 
GLOBOCON 2012 statistical data revealed about 951,600 newly diagnosed gastric 
cancer cases.  In 2012 deaths due to gastric carcinoma  worldwide was around  720,000 1. 
Gastric carcinoma is the fifth commonest malignancy in the world and the third most 
frequent malignancy causing death.  The sex ratio of gastric malignancy is 2:1 in males 
and females. The Eastern part of Asia (Korea> Mongolia>Japan> China) and Europe 
have the highest incidence of gastric carcinoma. The lowest incidence has been  recorded 
in Africa and Northern America 1.  Since 1990 interestingly, there is a reduction in gastric 
carcinoma mortality rates and the global incidence has been reducing gradually from the 
late eighties 2(See Table 1).  Diffuse type gastric carcinoma    is relatively increasing 
however, compared to intestinal type3.  A factor directly linked to this steady global 
decline of gastric carcinoma could be the increased availability of fresh vegetables, fruits 
and the availability of refrigerators which increase freshness and reduce salt based 
preservation. The invention of antibiotics and the improved quality and awareness of 
sanitation are other main factors which reduce chronic H. pylori infection. Reduction in 
smoking also reduced the prevalence in developed countries4. Gastric carcinoma ranks 
high among male cancers in South India. The prevalence of H. pylori infection is 
alarmingly high in India, and could be the reason the burden of stomach cancer is very 
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high. In addition to H.pylori, almost all of etiological risk factors for gastric carcinoma  
are present among the Indian population5. 
Table 1.Incidence comparison between GLOBOCON 2012, 2008, 2002 
GLOBOCON             2012             2008              2002 
male Female male female male Female 
East Asia 35.4 13.8 42.4 18.3 62.1 26.1 
E. Europe 20.3 8.9 22.2 9.7 29.6 12.8 
S.America 14.2 7.0 17.3 8.4 24.2 12.2 
West Asia 11.8 7.3 12.6 6.7 11.6 6.4 
S. Europe 11.7 5.9 14 6.8 18 8.7 
C.America 10.6 8.2 12.7 9.3 15.2 10.8 
*Age per standerdised rate per 100,000. E- Easter, S-Southern, C-Central 
ANATOMY OF THE STOMACH 
The stomach is a part of the gastrointestinal system which is continuous with the 
duodenum distally and the esophagus proximally. Its functions include food storage and 
also initiating the process of digestion. The stomach is divided into four parts Figure 
PYLORUS /ANTRUM: the pyloric antrum leads to the pyloric canal. BODY: The 
portion between the pyloric antrum and fundus. FUNDUS:  the proximal part of the 
stomach above the Gastro esophageal Junction. CARDIA: The part surrounding the 
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cardiac orifice. The lesser curvature is concave and shorter than the greater curvature 
which is convex and much longer. The incisura angularis demarcates the body and 
pylorus. Because of the short length of the lesser curvature, tumours in this site require 
total gastrectomy. The stomach wall comprises of four layers namely the mucosa, sub 
mucosa, muscularis propria and serosa. The anterior peritoneal lining is part of the 
greater sac, and the peritoneal lining on the posterior wall forms part of the lesser sac. 
There is minimal peritoneal lining on the posterior aspect of the gastro esophageal 
junction. 
 
Figure 1.Anatomic sub sites of the stomach 
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DEFINITION OF ADENOCARCINOMA STOMACH 
Adenocarcinoma of the stomach is a “Malignant gland forming neoplasm of the stomach, 
exclusive of the GEJ”. 
As per the latest AJCC 8th edition, tumours involving the GEJ with the tumour epicenter 
no more than 2 cm into the proximal stomach are staged as esophageal cancers. GEJ 
tumours with their epicenter located greater than 2 cm into the proximal stomach are 
staged as stomach cancers. Cardia cancers not involving the GEJ are considered as 
stomach cancers6. 
 
 
 
Figure 2.Definition of Gastric and GEJ carcinoma. (A) EGJ tumors with their epicenter located >2 cm into 
the proximal stomach are staged as stomach cancers. (B) Cardia cancers not involving the EGJ are staged as 
stomach cancers. (C) Tumors involving the EGJ with their epicenter <2 cm into the proximal stomach are 
staged as esophageal cancers. 
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ETIOLOGY 
Age 
Most patients presenting with  gastric carcinoma  are between50 and 70 years7.  Early 
onset gastric carcinoma (<40 years) is rare and has different etiologies. These early onset 
cases differ in their sex incidence (with either an equal male: female ratio or female 
predominance), morphology, (diffuse type rather than intestinal type), poor 
differentiation and have a poor prognosis8. 
Gender 
Gastric carcinoma shows a strong male predominance, with an approximately 2:1 male: 
female ratio6.The male prevalence of gastric carcinoma is greater in high incidence areas. 
There is a consistently higher male: female ratio in gastric carcinomas arising in the 
cardia compared to those affecting the distal stomach (antrum and pylorus). Early gastric 
carcinoma  shows a 1:1 or 0.9:1 male:  female ratio9. Globally gastric adenocarcinomas  
are more common in Asians than in whites6. 
AETIOPATHOGENESIS 
Gastric carcinoma is a multifactorial and multistep disease that often involves a ladder 
wise progression starting from normal gastric mucosa to chronic gastritis, atrophic 
gastritis and intestinal metaplasia. Thereafter multiple host and genetic factors contribute 
towards the development of dysplasia and carcinoma in situ, and ultimately to invasive 
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carcinoma10 (See figure3). Risk factors commonly involved in the evolution of gastric 
carcinoma are discussed in three broad categories: 
Environmental factors 
H.pylori infection is the prime culprit involved in the multiple steps leading gastric 
carcinoma by producing a lot of factors that disrupt the function of normal mucosal 
barriers and act as cancer promoters. These include the production of urease,  Cytotoxin 
associated gene A (CAG A ), Vacuolating gene A (Vac A),  Phospholipase production,  
Protease production, Upregulation of host immunity and hypochlorhydria, increased free 
radical production, decreased gastric anti oxidant levels, increased epithelial cell 
proliferation and increased risk of mutations11.  H.pylori activates the WNT signalling 
pathway with the help of β catenin.  Diets rich in salts and nitrites and diets low in 
antioxidants also form N nitroso compounds supporting carcinogenesis12 
 Host factors 
Intestinal metaplasia and chronic atrophic gastritis are the most common risk factors 
found in hosts13. Partial gastrectomies with bile reflux,  the presence of gastric adenomas 
with high-grade dysplasia, Autoimmune gastritis and Menetriers disease are other 
precursor lesions of  gastric adenocarcinoma14. 
  
 
26 
 
Genetic factors 
CDH1 gene (encoding E cadherin) germline mutation in individuals with a family history 
of gastric adenocarcinoma, the presence of  Familial Adenomatous Polyposis and 
Hereditary Non-polyposis Cancer Syndrome (HNPCC)  are primary genetic risk factors 
associated with the development of this malignancy15. 
. 
 
Figure3.Multistep gastric pathogenesis. 
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.CLINICAL FEATURES 
Gastric adenocarcinoma is a disease of insidious onset with variable clinical features and 
a frequent initial asymptomatic period. The initial presentation is often nonspecific with 
vague upper gastrointestinal symptoms including anorexia, nausea, vomiting and 
dyspepsia. Patients with more advanced lesions complain of epigastric mass, dysphagia, 
loss of weight, haematemesis and melaena.  Sister Mary Joseph nodule which is a 
subcutaneous umbilical nodule may be present and represents a periumbilical metastatic 
deposit. Additionally, there may be supraclavicular lymphadenopathy, commonly known 
as Virchow Trossier node, due to lymph node metastasis. Distinctive bilateral ovarian 
gastric adenocarcinoma metastases are known as Krukenburg tumours. Paraneoplastic 
syndromes  also are seen commonly such as Diffuse seborrheic keratosis,  Acanthosis 
nigricans,  Microangiopathic hemolytic anemia and  Trousseau’s syndrome16. 
DIAGNOSIS 
Gastric carcinoma is diagnosed on gastroscopy and biopsy. The diagnostic accuracy rate 
of endoscopy with biopsy for upper gastrointestinal cancers is more than 95%.  The 
diagnostic accuracy of biopsies usually increases with the increasing number of samples 
taken.  Six biopsies from lesions are advisable with two from the centre of the lesion and 
one from each quadrant. After diagnosing gastric carcinoma, computed tomography (CT) 
and endoscopic ultrasonography (EUS) are usually performed for tumour staging.   EUS 
is used for accurate estimation of the depth of tumour invasion for local staging.  The 
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accuracy of EUS for T staging in gastric carcinoma is approximately 82%. The sensitivity 
of EUS is 70% to 100% and specificity 87% to 100%.  CT scan is good for evaluating 
distant metastases to the lung, liver, bone, etc16. 
 
GROSS FEATURES 
Approximately 50% of gastric carcinoma s arise in the distal stomach (the pyloric part of 
the stomach), frequently involving the lesser curvature. 16% of gastric carcinoma s 
occurs in the proximal stomach (cardia, the upper third of the body and fundus) 
CLASSIFICATION SYSTEMS 
Numerous classifications for gastric adenocarcinoma exist, based on macroscopic and 
microscopic features.  These include The World Health Organization (WHO) system, 
Lauren classification, Ming classification and the Goseki classification.   Staging is the 
most significant predictor of the gastric carcinoma patient’s survival however, rather than 
of any of the pathological classification systems. 
 
Macroscopic - Bormann classification17 
The Type 1: Polypoid, Type 2: Fungating, Type 3: Ulcerated and Type 4: Infiltrating:  
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Figure 4.Bormann classification 
 
Microscopic classification 
Gastric adenocarcinoma accounts for approximately 95% of all malignant gastric 
neoplasms. Gastric carcinoma is well known for its heterogeneity and complexity in 
morphologic characteristics.  
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 In 1965   Lauren described the first primary histopatholgical classification system18. This 
classification divides gastric carcinomas morphologically into two types:    Diffuse type 
gastric carcinoma and intestinal type gastric carcinoma. 
The Lauren classification system18 
The intestinal type of gastric carcinoma is composed of large pleomorphic, mitotically 
active epithelial cells with large nuclei, prominent nucleoli and variable amounts of 
intracytoplasmic mucin. The tumour cells form glands, nests, sheets, tubules and may 
demonstrate papillary architecture. The diffuse type is predominantly composed of poorly 
cohesive or discohesive epithelial cells with mild nuclear hyperchromasia and minimal 
pale eosinophilic to clear cytoplasm, often infiltrating into a desmoplastic stroma. Signet 
ring morphology is often apparent. Gland formation is inconspicuous but appreciated 
within the superficial regions of a tumour (see Table 2). 
 
Modified  Lauren classification system19 
In this classification both Lauren’s pathological classification and the anatomical location 
of gastric cancer are included, forming three tiers of classification (see Table 3). 
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Ming Classification20. 
 Ming proposed (1977) another classification system of gastric carcinoma based on the 
expanding vs. infiltrative nature of the tumour growth and invasion pattern.  This is an 
important indicator of biological behavior with the expanding type adenocarcinoma 
growing predominantly by expansion with a sharply delineated periphery, and resulting 
in a nodular growth of a tumour, in contrast to the infiltrative type tumours that show 
diffuse infiltration of tumour cells into the layers of the gastric wall without forming 
masses or nodules. 
Table 2.Difference between intestinal and diffuse type gastric adenocarcinomas 
Features 
 
Intestinal Diffuse 
Age Old age Young age 
   
Sex M > F M = F 
   
Risk factors Helicobacter pylori infection, 
high salt diet, and smoking 
CDH1 gene mutation 
   
Precursors Adenoma or dysplasia Tubule neck dysplasia or 
signet ring cell carcinoma in situ 
   
Surrounding gastric mucosa Atrophic gastritis with 
intestinal metaplasia 
Non-atrophic gastritis or 
nonmetaplastic mucosa 
   
Common location Antrum and angulus  Corpus and whole stomach 
   
Gross feature Exophytic lesion Ulcerative lesion and linitis plastic 
   
Microscopy Well - developed tubular 
architecture 
Discohesive cells or signet ring cells 
   
Routes of spread Hematogenous spread Direct invasion into the surrounding 
organs 
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Table 3.Modified Lauren classification system 
Modified 
Lauren 
 Lauren Anatomical location 
   
   
PND 
 
 
Intestinal type Bulk (＞ 80%) located in the 
gastric fundus/ cardia. These 
tumours extended up to the GEJ. 
 
  
D Diffuse and mixed type located anywhere in the stomach 
   
DND Intestinal type Bulk was usually in the distal 
stomach, although they could 
extend up to the mid body of the 
stomach or down to the pylorus 
   
PND- Proximal non diffuse, D- diffuse, DND- Distal non diffuse  
Goseki classification21 
Classification system of gastric carcinoma based on the degree of tubular differentiation 
and the amount of intracellular mucin production  
Table 4.Goseki classification 
 
 
Goseki Tubular differentiation Intracellular mucin 
Group I: well-differentiated mucin poor 
Group II: well-differentiated mucin rich 
Group III: poorly differentiated mucin poor 
Group IV: poorly differentiated mucin rich 
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The WHO(2010) classification system22. 
World Health Organization (WHO) proposed a classification system based on traditional 
histopathology features and the degree of differentiation of gastric carcinoma.  
(For the histopathology of individual subtype with ICD definition, see Annexure 8) 
 
 
 
Papillary adenocarcinoma Tubular adenocarcinoma 
Mucinous adenocarcinoma Signet ring cell carcinoma 
Poorly cohesive carcinoma Mixed adenocarcinoma 
Parietal cell carcinoma Adenosquamous carcinoma 
Carcinoma with lymphoid stroma Hepatoid adenocarcinoma 
Squamous cell carcinoma, NOS Lymphoepithelial carcinoma 
Medullary carcinoma, NOS Undifferentiated carcinoma 
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TNM STAGING6. 
Depth of invasion 
X: Cannot be assessed 
pT0: No evidence of a primary tumour 
PTis: Carcinoma in situ/high-grade glandular dysplasia 
pT1: Tumor invades lamina propria, muscularis mucosae, or sub mucosa 
pT1a: Tumor invades lamina propria or muscularis mucosae 
pT1b: Tumor invades sub mucosa 
pT2: Tumor invades muscularis propria 
pT3: Tumor invades subserosal connective tissue, without involvement of visceral 
peritoneum or adjacent structure 
pT4: Tumor invades serosa (visceral peritoneum) or adjacent structures. 
 pT4a: Tumor invades serosa (visceral peritoneum) 
pT4b: Tumor invades adjacent structures (spleen, transverse colon, liver, diaphragm, 
pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum.) 
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Figure 5.T1 and T2 defintion.T1a is defined as tumor that invades the lamina propria. T 1b is defined as 
tumor that invades the sub mucosa. T2 is defined as tumor that invades the muscularis propria, whereas T3 is 
defined as tumor that extends through the muscularis propria into the subserosal tissue6 
 
 
 
Figure 6.T3 definition. T3 is defined as tumor that invades the subserosal, shown here is invading the lesser 
omentum without involvement o f the serosa (visceral peritoneum). Distal extension to duodenum does not 
affect the T3 category6 
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Figure 7.T4a and T4b definition.T4a is defined as tumor that penetrates the serosa (visceral peritoneum) 
without invasion of adjacent structures, whereas T4b is defined as tumor that radially invades adjacent 
structures, shown here invading the pancreas6 
 
 
37 
 
Regional Lymph Nodes (pN) 
NX: Cannot be assessed 
pN0: No regional lymph node metastasis 
 pN1: Metastasis in 1 to 2 perigastric lymph nodes  
pN2: Metastasis in 3 to 6 perigastric lymph nodes  
pN3: Metastasis in 7 or more per gastric lymph nodes 
pN3a: Metastasis in 7 to 15 perigastric lymph nodes 
pN3b: Metastasis in 16 or more perigastric lymph nodes 
Distant metastasis (pM1) 
A) Positive peritoneal cytology  
B)  Nonregional lymph nodes (hepatoduodenal, retro pancreatic, mesenteric, and para-
aortic) 
C) Peritoneal surfaces (Nodules implanted on the peritoneal surface are considered 
distant metastases (M1). 
D) Adjacent organs (spleen, transverse colon, liver, diaphragm, pancreas, abdominal 
wall, adrenal gland, kidney, small intestine, and retroperitoneum)  
Note: Mx deleted from AJCC 8th edition   
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TUMOUR GRADING6 
Grading is based on the 8th edition TNM tumour staging system. According to this 
system, gastric carcinomas are graded based on the extent of glandular differentiation. 
Grade X Cannot be assessed 
Grade 1 well differentiated (greater than 95% of a tumour composed of glands)  
Grade 2 moderately differentiated (50% to 95% of a tumour composed of glands)  
Grade 3 poorly differentiated (49% or less of a tumour composed of glands)  
Signet-ring cell carcinomas are high grade and are classified as grade 3.  
Small cell neuroendocrine carcinomas and undifferentiated carcinomas are classified as 
grade 4.  
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 
The HER2 protein also is known by other names like p185 or ErbB-2 is a 185-kDa 
transmembrane tyrosine kinase receptor. It is part of a family of 4 receptors (ErbB1-4), 
which have an effect on cancer pathogenesis23. In 1985, HER 2 was found to be 
amplified in breast carcinoma24. HER2 was the first molecule to be the focus of targeted 
therapy in a solid tumor. HER2 targeted molecule Trastuzumab, was approved by FDA 
for metastatic breast cancer in 1998, and for adjuvant chemotherapy for breast cancer in 
200625. HER 2 protein is encoded by the HER  proto-oncogene located on the long arm 
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of chromosome 1726. All four members of the ErbB family play a role in cancer 
progression by forming homo-dimers with another similar molecule or a heterodimer 
with other members of the ErbB family. Except HER 2, all other dimerizations are ligand 
induced. However, HER 2 can dimerize without a ligand and hence it is the preferred 
dimerizing partner for other members of the ErbB family. HER 2 receptor plays an 
important role because this receptor is constitutively active as a result of its special 
conformation. When  the HER 2receptoris over expressed, it will be the preferred binding 
partner for other family members and triggers signal transduction which affects cell 
growth, apoptosis, metastasis and angiogenesis in breast cancer. Studies suggest that the 
HER2 receptor plays a similar role in gastric cancer27. Due to this unique property, it is a 
primary driver in tumour proliferation and cancer cell survival28. Therefore HER 2 is a 
prime target in appropriately selected patients. HER 2 overexpression in gastric 
carcinoma was first described in 198624.  In literature, the overexpression of HER 2 has 
been reported worldwide in the range of 7% to 44 %29. HER 2 expression is associated 
with a worse prognosis 30.  A landmark trial using Trastuzumab as a therapeutic option in 
gastric carcinoma was the ToGA study. The results of this study showed a significant 
positive survival in patients with gastric carcinoma. The study administered Trastuzumab 
along with chemotherapy and compared the result with chemotherapy alone 31. The 
results of this study proved that adjuvant therapy with targeted Trastuzumab is useful in 
metastatic gastric carcinoma. After that studies focused on assessing the role of 
Trastuzumab in non-metastatic gastric carcinoma. Phase II trials give very good results in 
the management of advanced gastric carcinoma with Trastuzumab 32. There is a high 
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chance that Trastuzumab along with other targeted molecules will soon become an 
important part of the treatment of non-metastatic gastric carcinoma 33 
HER 2 AND GASTRIC CANCER 
Different studies have found HER 2 overexpression in gastric and gastro esophageal 
adenocarcinomas with increasing depth of invasion, lymph node involvement, distant 
metastases and poor survival. However, there is conflicting information and not all 
studies have shown a clear association between HER2 over expression and poor 
prognosis. HER2 protein overexpression and gene amplification are much more 
heterogeneous in gastric cancer compared to breast cancer. Prevalence of HER 2 show 
wide variation within and between populations. HER 2 over expression is usually more 
prevalent in the intestinal variant than diffuse variant29. In the Indian population, the 
expression of HER 2 has been reported to vary from 21 to 44%30.  
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HER 2 STATUS ASSESSMENT 
Accurate assessment of HER 2 status is essential to make sure that selected patients 
benefit from targeted therapies. HER 2 status is typically measured by 
immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH). IHC is more 
frequently utilized for HER 2 assessment due to its wider availability and lower cost.  
Hoffman et al developed one standardized validated scoring system for HER 2 
assessment in gastric cancer31. Cells that stain with a score of 0 or +1 are considered 
negative. A score of +3 is confirmed over expression, while +2 denote an equivocal 
positive score. Hoffman et al. have proposed grading criteria for the interpretation of 
HER2 staining by IHC in gastric cancer, which is different from the criteria, used for 
breast cancer staining. There were differences in the interpretation of biopsy and 
resection specimens also. Based on the staining pattern, four scores namely 0, 1+, 2+ and 
3+ are given.0 and 1+ staining is considered negative for HER 2.3+ staining as per the 
given criteria are considered positive for HER2.2+ staining is classified as equivocal and 
requires further testing using alternate methods like fluorescence in-situ hybridization 
(FISH), silver in-situ hybridization (SISH) or chromomeric in-situ hybridization (CISH). 
Particulars of the HER 2 IHC staining is as follows: Primary antibody: Ventana 
(Pathway) anti HER 2/neu (4B5) Rabbit Monoclonal Primary Antibody. 
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Procedure -MILD- 32 CC1 PROTOCOLIHC Stainer- Automated Ventana Benchmark 
XT (Standard operating protocol in Annexure 6). 
 
 
Figure 8.HER 2 IHC scoring system. A. 40x: HER2 0, No staining of tumor cells.  B.40x:  HER2 1+, Weak 
incomplete staining of >10 % cells, C.40x: HER2 2+, Weak complete staining of >10 % cells.  D. 40x: HER2 
3+ Strong complete staining of >10 % cells31 
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Table 5.Hoffman etal scoring for HER2 in gastric cancer 
  
Staining 
 
       Surgical specimen 
 
         Biopsy 
 
Interpretation 
    
    
 
 
 
0 
 
No reactivity or membranous 
reactivity in <10% of tumour 
cells 
 
No reactivity or no 
membranous reactivity in 
any tumour cell 
 
 
 
Negative 
    
 
 
1+ 
Faint or barely perceptible 
membranous reactivity in ≥10% 
of tumour cells; cells are 
reactive only in part of their 
membrane 
Tumour cell cluster with a 
faint or barely perceptible 
membranous reactivity 
irrespective of percentage of 
tumour cells stained 
 
Negative 
    
 
 
2+ 
Weak to moderate complete, 
basolateral or lateral 
membranous reactivity in ≥10% 
of tumour cells 
Tumour cell cluster with a 
weak to moderate complete, 
basolateral or lateral 
membranous reactivity 
irrespective of percentage of 
tumour cells stained 
 
 
Equivocal 
    
 
 
3+ 
Strong complete, basolateral or 
lateral membranous reactivity in 
≥10% of tumour cells 
 
Tumour cell cluster with a 
strong complete, basolateral 
or lateral membranous 
reactivity irrespective of 
percentage of tumour cells 
stained 
 
 
Positive 
Hoffmann etal31 
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HER 2 IHC TESTING AND VARIABLES. 
Variability in HER2 testing can arise from pre-analytic, analytic, and post-analytic 
factors. The relevance of these factors varies according to the measurement technique 
(e.g., IHC vs. FISH) but each may affect the accuracy, reliability, and reproducibility of 
results. 
Pre-analytic factors 
The time of fixation is one major factor.  Biopsies or resection specimens must be placed 
in the recommended fixative as quickly as possible to retain proper antigenic properties. 
The minimum fixation time recommended is 6–8 hrs for a small biopsy and for surgical 
resections, 24hrs to 48 hrs. Prolonged fixation also should be avoided (>48 hrs). 
Prolonged fixation will reduce the staining pattern of HER 2 and leads to false negative 
results or equivocal results32. Mucosal biopsies often receive insufficient fixation, which 
results in false negative results. The ASCO/CAP Guidelines recommend recording 
information related to these pre analytic factors as standard procedure33. 
Analytic factors. 
Formalin adversely affects epitopes, and proper antigen retrieval steps are required for  
antibodies detection32. Tissue staining patterns will be affected by the antigen retrieval 
solution and its composition. Automated immunostaining methods are always 
superior because they reduce all variables associated with technical factors. Even with 
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Automation however, there are potential sources of error including differences in the 
optical density of blocks32. 
Post-analytic factors. 
Post-analytic factors relate to the interpretation of assay findings, image analysis, 
reporting, and ongoing quality assurance. Interpretation and cut off values are a primary 
source of variability both within and between laboratories. Assessing parameters for IHC 
scoring is greatly influenced by inter- observer and intra-observer variability  and are also 
affected byte use of positive controls for different levels of staining with each batch34. 
The 0–3+ scoring system used to assess HER2 immunostaining differs from other scoring 
systems used to define cutoffs with other IHC markers. Interpretation is usually 
performed manually and results can vary depending on the experience and alertness of 
the observer. Scoring with FISH and newer HER2 Testing techniques are more objective 
and quantitative than with IHC. Image analysis has been proposed as a means of 
improving the objectivity of IHC interpretation and reducing intra-observer 
variability34.Genetic factors complicating HER2 test interpretation are discussed under 
HER 2 and heterogeneity. 
HER 2 AND HETEROGENEITY 
Heterogeneous gene amplification results from two or more distinct or fusion clones of 
tumour cells displaying different gene amplification patterns. There will be mixed areas 
with amplified and absence of amplified   HER2.  This variation in amplification can 
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results in discordance in IHC or FISH assessment, directly affecting the HER2-targeted 
therapy35.  Gastric carcinoma is well known for heterogeneity in HER2 expression which 
is detected mainly in IHC 2+ cases or mixed histological types36.  Overexpression of 
HER2 protein is associated aggressive biological behavior37. From sampling to scoring, 
heterogeneity will adversely affect test results, including the incidence of false negative 
status.  More than intratumoral heterogeneity, heterogeneity of  HER2 status between 
primary and metastatic gastric tumours is common 38. This difference suggests that HER2 
amplification and overexpression can occur de novo in distant metastases in late stage 
disease and that genetic divergence occurs at the time when in situ cancers progress to 
invasive cancers. This could also impact patients’ eligibility for HER2-targeted therapy39. 
Therefore, in stage IV disease, HER2 testing should ideally be performed on samples 
from both primary and distant metastatic sites38.  
HER 2 AND TARGETED THERAPY  
HER 2 status and the use of molecular targeted therapy in the management and 
prognostication of the gastric carcinoma is very important. Surgical resection is the 
primary and recommended surgical treatment, although most patients are diagnosed at an 
advanced stage in which chemotherapy is the main treatment option. The efficacy of 
treatment for advanced gastric carcinoma with palliative chemotherapy is poor, so there 
is great interesting the targeted therapies that are emerging, and several molecular 
targeting agents are being tested. Unfortunately,   Trastuzumab is the only targeted 
therapy that has a proven survival benefit in gastric carcinoma till date40.  Trastuzumab 
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inhibits the HER 2 receptor.   Tyrosine kinase activation is effectively blocked by binding 
the juxtamembrane portion of HER 2 receptor using very two specific antigenic sites of 
Trastuzumab. Tumor genesis is prevented by Trastuzumab by not allowing HER 2 
protein to undergo heterodimerization. HER 2-mediated signaling is inhibited by raising 
the antibody-dependent cellular cytotoxicity and cleavage of the extracellular domain of 
HER 2 is also inhibited41. In gastric carcinoma patients with overexpression of HER 2, 
the addition of Trastuzumab cisplatin resulted in better response rate (35%) and stable 
disease (17%).  The efficacy and safety of  Trastuzumab were evaluated in HER 2 
positive advanced gastric carcinoma  by  Trastuzumab for Gastric Cancer Trial 
(ToGA),the largest multicentric trial for targeted therapy HER 2(42).  Were randomized 
to treatment with chemotherapy alone vs.  Trastuzumab  with 5FU/capecitabine and 
cisplatin. Preliminary results showed better median survival with the combination regime 
(13.5 vs. 11.1 months), with a reduction in risk of death (26%).   In the pre-planned 
analysis, HER 2 positive patients (IHC2+/FISH+ or IHC3+) showed a better survival 
trend  with longer survival (16 months) with  Trastuzumab and chemotherapy compared 
with chemotherapy alone (11.8 months)42. 
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MATERIALS AND METHODS 
 
STUDY SETTING 
This study was conducted in Christian Medical College, Vellore in the department of 
General pathology on 66 consecutive mucosal biopsies with sufficient tumor and 
corresponding gastrectomy specimens of gastric adenocarcinoma diagnosed between July 
1, 2016, and June 30, 2017. The clinic pathological details were reviewed systematically 
from the electronic medical work station, and Radiological, and endoscopy details were 
retrieved wherever possible from the same. The haematoxylin and eosin stained slides 
were reviewed for classification, grading and staging. Immunostaining for HER 2 was 
performed on freshly cut sections and the positive staining graded (intensity, pattern and 
of positive tumor cells). If both mucosal biopsies and resected tissue were available in a 
case, both sections were placed on the same slide for simultaneous IHC staining. HER 2 
expression of the tumor cells was correlated with the anatomical site, classification, 
staging and grading of a tumor. The data on mucosal biopsies and surgical resections was 
analyzed separately. Correlation of HER 2 expression on mucosal biopsies versus 
surgical resections was also performed. Any discordance in matched resection and biopsy 
specimens was analyzed for heterogeneity. In all HER 2 positive cases, IHC was 
performed in multiple blocks from all quadrants of the tumor to demonstrate intratumoral 
heterogeneity. 
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RESEARCH  BUDGET PLAN. 
Institutional review board (IRB) Minutes number: 10206approved our study. 
Interdepartmental collaboration between General Pathology, Medical Oncology, General 
Surgery and Gastroenterology significantly improved the quality of our research. The 
Institutional Fluid Research grant account number (22 Z 141) was used to cover the costs 
of IHC staining. 
SAMPLE SIZE:  
The  aim of the study the prevalence of HER 2 expression in gastric adenocarcinoma by 
IHC and to correlate the expression HER 2 with the stage, grade, classification and 
location of gastric adenocarcinoma. The expression of HER 2 was separately evaluated in 
mucosal biopsies and surgical resections and in those patients where both were available, 
the expression was correlated. Patients who had consecutive mucosal biopsies with 
sufficient tumour and corresponding resected specimens of gastric adenocarcinoma 
diagnosed in our hospital (resection specimens) from July1st 2016 to July 30th 2017 were 
recruited into our study. Preliminary analysis showed that the sample size required was 
approximately 66 cases to meet the objectives of the study.  
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SAMPLE SIZE CALCULATION: 
The sample size was calculated using nMaster 2.0 software. The formula used was 
Sample size calculation using prevalence. 
n= sample size                 e= ± level of precision around estimated HER 2 prevalence 
 p= prevalence of HER 2 over expression 
Zα = 1.96 area under the standard normal curve representing  
(95% confidence interval.)  
1- P= 1 – prevalence of HER 2 expression 
Assumptions: Precision = 10.00 %, Prevalence = 22.00 % (TOGA trial) 
 Population size = infinite 
Estimated sample size: n = 66 
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 PARTICIPANTS: 
Inclusion criteria 
Patients with a confirmed histological diagnosis of gastric carcinoma with sufficient 
tumour tissue for immunohistochemistry. 
Exclusion criteria 
Scanty tumour biopsies 
GEJ carcinoma patients 
Patient’s resection performed in another hospital. 
 Patients histological diagnosed as secondary tumour or distal Squamous cell carcinoma 
of the esophagus. 
BIAS: 
Cases were identified only by the number so that all investigators were blinded. All 
investigators reached agreement on the particular score by consensus to minimize bias. 
DATA SOURCES/MEASUREMENT: 
Patient data was collected from completed proforma and the institutional electronic work 
station. 
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QUANTITATIVE VARIABLES: 
The variables analyzed in this study are listed in the proforma (see Annexure 1); 
Immunohistochemical markers were graded according to the score provided in the 
literature review. 
STATISTICAL ANALYSIS: 
The attached proforma was used for data collection. 72 mucosal biopsies and the 
corresponding resection specimens of gastric carcinoma that met the inclusion criteria 
were studied. Data entry was done in EPIDATA software and used for statistical analysis.  
Results on continuous measurements presented as Mean, and SD (Min-Max) and results 
on absolute measurements are shown in   Number   (%).   The significance was assessed 
at 5 % level of significance.  . Student t-test was used to find the significance of study 
parameters on the continuous scale between two groups on metric parameters.  Chi-
square/ Fisher Exact test has been used to determine the significance of study parameters 
on a categorical scale between two or more groups. All the tests of associations or 
comparisons were considered significant at 5% (p value≤0.05) level of significance. Most 
of the findings and results are presented using tables and graphs.  All statistical Analysis 
was performed with the help of a professional statistician using SPSS and Microsoft 
Excel software. 
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METHODOLOGY 
The study utilized 72 matched mucosal biopsies, and the corresponding surgical 
resections of the same patients who were diagnosed with gastric carcinoma in the 
Department of Pathology from 1 July 2016to30 June 2017. As soon as the specimen was 
received from the operation theatre, Specimens were fixed in neutral buffered formalin 
(10%) See figure. 15 to 20 times the volume of the specimen was used for formalin 
fixation. For gastric resection specimens, 18- 24 hours was recommended, and the 
interval between tissue acquisition and fixation was kept as short as possible (< 1 hour). 
Because of the high probability of gastric heterogeneity, a minimum of 6 gastric biopsy 
fragments were taken from different areas. The standard grossing procedure was 
followed. A minimum of four sections through a wall, including tumour borders and 
adjacent mucosa were submitted for paraffin block preparation and haematoxylin and 
eosin staining (H&E). Fixation was performed at room temperature (15- 25°C). 
Processed tissues were embedded in new paraffin.  Prolonged incubation in molten 
paraffin was meticulously avoided as high temperatures can degrade epitopes. 
Concerning surgical samples, the pathologist would select tissue blocks with the largest 
area of intestinal differentiation (glandular structures) for HER2 staining. The use of pre 
diluted VENTANA HER2 (4B5) and corresponding  Detection Kits, in combination with 
a VENTANA automated slide stainer Benchmark XT( See figure10 )reduced the 
possibility of human error and inherent variability resulting from individual reagent 
dilution, manual pipetting, and manual reagent application. 
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Figure9. Specimen fixation. Total gastrectomy specimen with Fungating growth in the lesser curvature cut 
opened along, the lesser curvature and fixed with the pin into the wax board before fixing with 10% formalin 
solution. 
55 
 
 
Figure 10.Ventana Bench Mark XT. 
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STUDY ALGORITHM 
 
Mucosal biopsies and resected specimen of Gastric 
                        adenocarcinoma cases  
 
 
      Review of all slides and study of tumour characteristics 
 
                    
Selection of representative tissue blocks and run IHC –HER -2 
                            (Ventana Benchmark XT) 
 
 
                    Assessment of expression of IHC-HER-2 
 
 
 
           Analysis and comparison of histopathology with 
                                 Immunohistochemistry 
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RESULTS 
 
CLINICAL FEATURES 
The study was conducted in a tertiary hospital in south India on a total of 72 cases of 
gastric adenocarcinoma diagnosed over period of one year from 2016-2017. 49 patients 
were male (68%), with a sex ratio of 2.1:1. The mean age of patients was 53 years (range 
23 years to 82 years, with a standard deviation of 12.53). The mean age of female 
patients alone was 46 years suggesting that women may have gastric adenocarcinoma 
stomach at a younger age the highest incidence of gastric carcinoma, both in women and 
men in our study, was found in the fifth decade of life. Majority of the patients in the 
study were from West Bengal and Bangladesh. This could be a reflection of the patient 
population attending our hospital. Patients from Tamil Nadu were the next most frequent. 
Among the surgical specimens, 55 were distal subtotal gastrectomies, and 17 were total 
gastrectomies.         
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Figure 11.Distribution of patients by age 
 
Figure 12.Distribution of patients by place 
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Figure 13.Distribution of patients by sex 
 
 
Figure 14.Distribution of patients by Surgery 
60 
 
PATHOLOGICAL FEATURES 
The following pathological parameters were evaluated. 
TUMOR LOCATION 
In 58(80.5%) cases, the tumor was located in antrum/pylorus.  In 3 cases (4%) the tumor 
was found in body of the stomach, in 9cases (12.5%) in the fundus/cardia of the stomach, 
and in 2 (3%) cases carcinoma involved the whole stomach.  46 (63.89%) exhibited a 
circumferential growth pattern, 21 cases (29.17%) were located in the lesser curvature of 
the stomach, and 5 cases (7%) in the greater curvature of the stomach. 
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Figure 15.Distribution of cases of gastric cancer depending on curvature 
 
Figure 16.Distribution of cases of gastric cancer depending on location 
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CLASSIFICATION 
BORMANN CLASSIFICATION: The most common form of advanced gastric 
carcinomas was Bormann type III    (Ulcerated) observed in 33 patients (45%), followed 
by type II in 21 cases (29%). (SeeFigure17). 
WHO 2010 CLASSIFICATION: According to the WHO classification, of the 72 cases 
of gastric carcinomas, 25(34.7%) cases were classified as tubular adenocarcinoma,   27 
cases (37.5%) as poorly cohesive carcinomas and 6 (8, 3%) as signet ring cell carcinoma.   
12 cases (16.7%) were classified as mixed adenocarcinoma.  1 (1.3%) cases were 
classified as mucinous adenocarcinoma.  1 (1.3%) cases classified as lymphoid stroma 
variant adenocarcinoma (see Figure18). 
LAUREN CLASSIFICATION: Based on the Lauren classification of gastric 
carcinoma, 26 were intestinal type carcinomas (36.1%),   44 diffuse type carcinomas 
were (61.1%). A tiny percentage of gastric carcinomas, 2% (3 cases), were indeterminate. 
(See Figure19). 
MODIFIED LAUREN CLASSIFICATION: Based on the Modified Lauren 
classification of gastric carcinoma, 6wereproximal non-diffuse carcinomas (PND) 
(8.33%), 45diffuse carcinomas (D) (62.5%) and 21 distal non diffuse (DND) type 
carcinomas (29.17%). (See Figure20). 
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Figure 17.Distribution of cases according to Bormann classification 
 
Figure 18.Distribution of cases according to WHO classification 
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Figure 19.Distribution of cases according to Lauren classification. 
 
Figure 20.Distribution of cases according to Modified Lauren classification 
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TUMOR GRADE 
1(1.39%) was a well-differentiated adenocarcinoma (G1), 29 (40.3%) - moderately 
differentiated adenocarcinoma (G2) and 42 (58.3%) - poorly 
differentiatedadenocarcinomaG3 (see Figure21) 
 
Figure 21.Distribution of cases according to tumor grade 
DEPTH OF INVASION (T) 
Carcinoma was limited to the mucosa in 3 patients (4.17%).  2 (2.8%) of cases were 
confined to the sub mucosa.  In seven there was muscular coat invasion (9.7%).  In 
22cases, invasion was limited to the subserosal connective tissue (30.6%) and in 38 
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(52.8%) cases, adenocarcinoma invading the gastric wall entirely, reaching the peri 
gastric fat. (See Figure 22). 
LYMPH NODE AND DISTANT METASTASIS 
Lymph node metastases were present in 60 cases (83 %%). 1 case had liver metastasis. 
(See Figure 23&24). 
 
 
Figure 22.Distribution of cases according to depth of invasion 
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Figure 23.Distribution of cases according to regional lymph node metastasis 
 
Figure 24.Distribution of cases according to distant metastasis 
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STAGING  
The highest numbers of cases were stage III disease in which curative oncological 
treatment was difficult to achieve. 48tumours were in stage III (66.8 %), 16 in stage II 
(22.1%) (See Figure25). 
LYMPHO VASCULAR AND PERINEURAL INVASION 
Lymph vascular invasion and Perineural invasion were found in28 cases (38.9%), and 
in44 cases (61.1%) respectively. (See Figure 26&27). 
PRECANCEROUS CONDITION 
Gastric mucosa adjacent to the tumor was evaluated for various additional findings.  11 
out of 72 (15.28 %) patients showed H.pylori infection with associated gastritis. 5 
(6.94%) cases showed Intestinal metaplasia.  (See Figure 28). 
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Figure 25.Distribution of cases according to pTNM stage 
 
Figure 26.Distribution of cases according to Lympho vascular invasion 
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Figure 27.Distribution of cases according to Perineural invasion 
 
Figure 28.Distribution of cases according to precancerous condition 
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PROXIMAL MARGIN 
Proximal Margin was involved in 3 (4%) of the resected specimens. 
DISTAL MARGIN 
Distal Margin was involved in 6 (8%) of the cases. 1 patient had involvement of both the 
margins. 
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Figure 29.Proximal margin involvement 
 
Figure 30.Distal margin involvement 
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NEOADJUVANT THERAPY: 
14 of 72   patients (19.4 %) had received neoadjuvant chemotherapy, and Tumour 
regression score evaluated. Out of these 14 cases, 5 (6.9) cases showed a poor response, 
3(4.1%) cases showed minimal response and 6 cases showed a moderate response. 
(See Figure31). 
 
 
Figure 31.Distribution of cases according to neoadjuvant therapy cases 
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HER 2 IHC STUDY 
 
HER2 AND DEMOGRAPHY 
On Immunohistochemical analysis, eight cases were positive (3+; 11.1 %) for HER2 
protein over expression and 64 cases were negative (88.9 %).  In this study, there were no 
equivocal cases (2+).  IHC HER 2 expression was found more often in men, but the 
correlation between HER2 expression and patients’ gender was insignificant (see table 
6).Correlation between HER2 expression and patient’s geographical location was also 
found to be insignificant. (See table 6). 
HER 2 EXPRESSION AND CLASSIFICATIONS 
There was a positive association between HER2 expression and tumours classified as   
WHO mixed adenocarcinoma (5/12 (41.7%), P=0.009).Bormann ulcerated variant also 
showed increased HER 2 positivity, but this was not statistically significant.   Laurens, 
Modified Lauren and Bormann classification parameters in our study did not show 
significant association with HER2 expression. For detailed comparison see (table 7). 
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Table 6.Association between HER2 status and clinic statistical parameters 
 Overall 
 n=72(100%) 
HER2 
positive  
8(11%) 
HER2 
Negative 64(89%) 
P value 
(Significant<0.05%) 
Age    1 
<50 yrs 26(36.11) 3(37.5)               23(35.94)  
>50 yrs 46(63.89) 5(62.5) 41(64.06)  
Gender    0.422 
Male 49 (68) 7(87.5) 42(65.62)  
Female 23(32) 1(12.5) 22(34.38)  
Tumor topography    0.173 
Distal antrum 58(80.56) 5(62.5) 53(82.81)  
Body 3(4.17) 0(0.0) 3(4.69)  
fundus/cardia 9(12.5) 3(37.5) 6(9.38)  
whole stomach 2(2.77) 0(0.0) 2(3.13)  
Tumour curvature    0.836 
Lesser 21(29.17) 3(37.5) 18(28.13)  
Greater 5(6.94) 0(0.0) 5(7.81)  
Circumferential  46(63.89) 5(62.5) 41(64.06)  
Place    0.973 
Bangladesh 23(31.94) 3(37.5)  17(26.56)  
West Bengal 23(31.94) 3(37.5) 20(31.25)  
Tamil nadu 17(23.61) 2(25.0) 15(23.44)  
Jharkhand 7(9.72) 0(0.0) 7(10.94)  
A.Pradesh 3(4.17) 0(0.0) 3(4.69)  
Nepal 1(1.39) 0(0.0) 1(1.56)  
Odisha 1(1.39) 0(0.0) 1(1.56)  
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Table 7.Association between HER2 status and classifications 
 Overall 
 n=72(100%) 
HER2 positive  
   8(11%) 
HER2 negative 
64(89%) 
P value 
(Significant<0.05%) 
Bormann     0.637 
Type I 0(0.0) 0(0.0) 0(0.0)  
Type II 21(29.17) 2(25.0) 19(29.69)  
Type III 33(45.83) 5(62.5) 28(42.75)  
Type IV 18(25.00) 1(12.5) 17(26.56)  
Laurens     0.572 
Intestinal 26(36.11) 4(50.0) 22(34.38)  
Diffuse 44(61.11) 4(50.0) 40(62.5)  
Indeterminate 2(2.78) 0(0.0) 2(3.13)  
Modified Laurens    0.593 
PND 6(8.33) 1(12.5) 5(7.81)  
D 45(62.5) 4(50.0) 41(64.06)  
DND 21(29.17) 3(37.5) 18(28.13)  
WHO(2010)    0.009 
Tubular  25(34.72) 3(37.5) 22(34.38)  
Papillary 0(0.0) 0(0.0) 0(0.0)  
Poorly cohesive 27(37.5) 0(0.0) 27(42.49)  
Signet ring cell 6(8.33) 0(0.0) 6(9.38)  
Mucinous  1(1.39) 0(0.0) 1(1.56)  
Mixed  12(16.67) 5(62.5) 7(10.94)  
Lymphoid stroma 1(1.39) 0(0.0) 1(1.56)  
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HER 2 AND HISTOPATHOLOGY 
Five of 29 moderately differentiated Tumours showed HER2 positivity.  The minimum 
and maximum tumour size ranged between 7 mm and 120 mm (average 49.86 mm).  
When HER2 protein expression correlated with tumour grade, moderately differentiated 
tumours were found to be the most standard grade with HER2 expression, but this was 
not statistically significant (P= 0.34).  Correlation between HER2 protein over expression 
and depth of invasion, lymph node metastasis, and distant metastasis not were found to be 
significant. There were no IHC 2+ cases. Therefore, cases with a final HER2positive 
status were exclusively composed of IHC 3+ Tumors and comprised 11.1 % of all gastric 
carcinoma s in this series. For detailed comparison (see table8). 
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Table 8.Association between HER2 status and histopatholgical parameters 
 Overall 
n=72(100%) 
HER2 positive  
   8(11%) 
HER2 negative 
64(89%) 
P value 
(Significant<0.05%) 
     
Tumour grade     0.34 
Grade I 1(1.39) 0(0.0) 1(1.56)  
Grade II 29(40.28) 5(62.5) 24(37.5)  
Grade III 42(58.33) 3(37.5) 39(60.94)  
Depth of invasion    0.53 
pT1a 3(4.17) 0(0.0) 3(4.69)  
pT1b 2(2.78) 0(0.0) 2(3.13)  
pT2 7(9.72) 2(25.0) 5(7.81)  
pT3 22(30.56) 5(62.5) 17(26.56)  
pT4a 38(52.78) 1(12.5) 37(57.81)  
pT4b 0(0.0)    
Regional L.N    0.859 
pN1 12(16.67) 1(12.5) 11(17.19)  
pN2 14(19.44) 1(12.5) 13(20.31)  
pN3a 16(22.22) 2(25.0) 14(21.88)  
pN3b 23(31.94) 4(50.0) 19(29.69)  
Distant metastasis    1 
pM0 71(98.61) 8(100.0) 63(98.44)  
pM1 1(1.39) 0(0.0) 1(1.56)  
TNM Staging    0.795 
Stage IA 1(1.39) 0(0.0) 1(1.56)  
Stage IB 6(8.33) 1(12.5) 5(7.81)  
Stage IIA 7(9.72) 0(0.0) 7(10.94)  
Stage IIB 9(12.5) 1(12.5) 8(12.5)  
Stage IIIA 20(27.78) 2(25.0) 18(2813)  
Stage IIIB 20(27.78) 4(50.0) 16(25.0)  
Stage IIIC 8(11.11) 0(0.0) 8(12.5)  
Stage IV 1(1.39) 0(0.0) 1(1.56)  
Proximal margin    0.301 
Negative 69(95.83) 7(87.5) 62(96.88)  
Positive 3(4.17) 1(12.5) 2(3.13)  
Distal margin    0.52 
Negative  66(91.67) 7(87.5) 59(92.19)  
Positive 6(8.33) 1(12.5) 5(7.81)  
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Table 9.Association between HER2 status and histopatholgical parameters (contd) 
 Overall 
n=72(100%) 
HER2 
positive  
8(11%) 
HER2 negative 
64(89%) 
P value 
(Significant<0.05%) 
     
Lymphovascular invasion     0.049 
Positive  28(38.89) 6(75.0) 22(34.38)  
Negative  44(61.11) 2(25.0) 42(65.63)  
Perineural invasion    0.248 
Positive  44(61.11) 3(37.5) 41(64.06)  
Negative  28(38.89) 5(62.5) 23(35.94)  
Precancerous condition      
Non identified 53(73.61) 6(75.0) 47(73.44) 0.443 
H. pylori gastritis 11(15.28) 1(12.5) 10(15.63)  
Intestinal metaplasia 5(7.81) 0(0.0) 5(7.81)  
Dysplasia 3(4.17) 1(12.5) 2(3.13)  
Treatment effect    0.34 
Grade 0 0(0.0) 0(0.0) 0(0.0)  
Grade 1  1(1.39) 0(0.0) 1(1.56)  
Grade 2 29(40.28) 5(62.5) 24(37.5)  
Grade 3 42(58.33) 3(37.5) 39(60.94)  
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HER 2 COMPARISON BETWEEN BIOPSIES AND RESECTION 
HER 2 positive status between matched mucosal biopsy and surgical resections shown in 
the table 10and 11).  66 cases (91.9 %) displayed complete concordance between IHC 
results on mucosal biopsies and corresponding resection specimens (64 IHC 0/1+ cases 
and 2 IHC 2/3+ cases). Among the 8 HER 2 positive (3 +) cases, 4 cases Showed good 
concordance between Resection and mucosal biopsies. Other   4 cases exhibited variable 
results on endoscopic biopsies and surgical blocks.   Two cases show positive shift which 
means, mucosal biopsy   IHC displayed a HER 2 score 0 and the Resection specimen 
showed IHC positivity (3+).  Other two cases revealed a negative shift which means 
mucosal biopsies showed HER 2 positivity with IHC score 3+ and were HER 2 negative 
for the matched resection blocks. The negative shift could have mainly been due to the 
chemo therapeutic effect. 
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Figure 32.Distribution of cases according to Resection HER 2 status 
 
Figure 33.Distribution of cases according to Biopsy HER 2 status 
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Table 10. HER 2 IHC status 
 HER 0 
 
HER 
1+ 
 
HER 
2+ 
 
HER 
3+ 
 
POSITIVE NEGATIVE HER %    
        
RESECTION 61 4 0 7 7 65 9.72% 
        
BIOPSY 63 3 0 6 6 66 8.33% 
        
 
 
 
Table 11.Concordance of HER2 Status by IHC in Biopsy and Surgical Samples 
Biopsy Samples                Surgical  Samples 
  
NPV (%) PPV (%) 
 IHC 0 to 1+ IHC 2+/ 3+ Total    
IHC 0 to 1+ 64(98.46) 2(28.57) 66(91.67)  98.462% - 
IHC 2+ to 3+ 1(1.54) 5(71.43) 6(8.33)  - 62.5% 
Concordance rate: 95.83     
NPV: negative predictive value. PPV: positive predictive value. 
 
 
HER 2 STATUS AND INTRATUMORAL HETEROGENEITY 
Intra tumoral heterogeneity evaluated in the surgical specimens only.  All   60   HER 2 
negative cases in the resection block were homogeneously negative.   12 cases showed 
positive immunostaining (IHC score 1+, 2+, or 3+).  4 cases showed a complex pattern 
and all of these scored 3+. Out of 8 HER 2positive cases3 cases had given adjuvant 
chemotherapy.  In all HER 2 positive   (3+) cases, sections from two separate surgical 
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paraffin blocks evaluated for staining.  NACT resection samples excluded from assessing 
the heterogeneity.  Complete correspondence between blocks seen in 2 cases and the 
remaining 3 cases comparison between blocks provided different results.  Intratumoral 
heterogeneity and WHO mixed adenocarcinoma show the significant relationship, and in 
these cases neoplastic glandular areas stained strongly with HER2. Two cases showed 
homogeneous staining pattern (3 +), and both cases were Tubular variants of the WHO 
classification (2010), and of the intestinal type (Laurens) with tumour grade II. All 3 
Cases displaying intratumoral heterogeneity were mixed adenocarcinoma (WHO 2010) 
with tumour Grade II and Grade III (See Table 12) 
 
 
Table 12.Tumour heterogeneity in HER 2(3+) positive cases 
 
Cases scenarios 
WHO 2010 
 
NACT HER2 
positive 
biopsy 
HER2 
positive 
resection 
Tumour heterogeneity 
      
Case 5  Mixed Non NAC 0 3+ present 
Case 15 Tubular Non NAC 3+ 3+ Absent  
Case 35 Mixed Non NAC 3+ 3+ present 
Case 59 Tubular Non NAC 3+ 3+ Absent 
Case 60 Mixed Non NAC 3+ 3+ present 
Case 62 Tubular NAC 3+ 0 NA 
Case 64 Mixed NAC 0 3+ NA 
Case 68 Tubular NAC 3+ 0 NA 
      
NA:  Not applicable (Patients who received neo adjuvant chemotherapy (NAC) excluded) 
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DISCUSSION 
 
 
In this study, we compared HER2 expression in matched mucosal biopsies and surgical 
specimens of patients with gastric adenocarcinoma. We also correlated HER 2 expression 
with important prognostic pathological parameters, the inﬂuence of non-Trastuzumab 
containing neo adjuvant chemotherapy (NAC) on this expression and studied tumour 
heterogeneity among the specimens with HER 2 positivity. 
PREVALENCE 
We found a HER2-positive status in11.1 % of all samples.  The   TOGA study represents 
one of the largest sets of HER2 testing data in gastric carcinoma samples, obtained from 
patients from 24 different countries in Asia, Europe and Latin America.  The HER2 
positivity rate in the ToGA study was 22% (810 of 3,665 patients) and is twice the 
prevalence we found in our series. However when the IHC results alone were considered 
only 398 cases (10.9 %) were HER2 positive (3+). In our study, since there were no 
tumours with IHC 2+ score, the final HER2 positivity prevalence was11.1 %,   matching 
with the IHC findings of the international TOGA trial.   
The prevalence of HER 2   is known to vary between populations. The present study 
exclusively examined gastric carcinoma and the expression of HER2 by IHC. Gastric 
adenocarcinoma reported a broad range of HER 2 over expression ranging from 7.6% to 
44.2 %( seeTable.13).  This variation may be due to various factors such as methodology, 
85 
 
different primary antibody clones, various IHC protocols, various IHC scoring systems, 
standard operating protocol, and differences in the reporting protocol, tumour 
heterogeneity and population heterogeneity studied. In the current study, a HER2 protein 
over expression of 11.1 % correlates with the findings of other international global 
studies and similar Indian studies. (See Table13), Sekaran et al. in a study conducted in 
Hyderabad, India observed 44.2 % HER2 positivity. Although genetic variation, dietary 
habits or precancerous conditions may affect HER 2 positivity rates in gastric carcinoma 
around the world,   the exact relationship between these factors and HER 2 expression is 
still unknown. The Ventana pathway using rabbit monoclonal antibody (4B5) was used to 
perform IHC in the TOGA trial and our current study. When compared to 4b5 clone, 
other tests (eg: HercepTest) report a lower sensitivity for the detection of HER2 protein 
expression. Data on HER2 expression in Indian patients with gastric carcinoma is 
insufficient, and there is a wide variation in published results. 
AGE AND GENDER 
Most studies show no association between HER 2 expression and age or sex of the 
patient, except  for the studies by Matsusaka et al. and FAN et al. that showed a 
statistically significant correlation(P=0.001) with the male gender. For further detailed 
comparison between similar studies global population and Indian population see 
(Table14) 
86 
 
Table 13.HER 2 studies with global prevalence 
Study  Place and year Patients    HER2IHC in % 
Bang YJ et al 42  ToGA trial(2010) 3,665 16.6% 
Cho J et al 43  S. Korea (2013) 2,798 7.3% 
Shan L et al 44  China  ( 2013) 1,463 9.8% 
Matsusaka et al45  Japan (2015) 1,461 15.6% 
Cappellesso et al46  Europe (2015) 1,040 11.0% 
Phan etal47  Vietnam(2017) 208 24.5% 
Yoshida et al48  Japan (2014) 207 17 % 
Hofmann et al31  Germany (2009) 178 10.7% 
Laboissiere et al49  Brazil (2015) 124 10.5% 
Hadi etal50  Egypt (2012) 85 14.2% 
Gharsalli T etal51  Tunisia (2017) 84 10.5% 
Ogun et al52  Nigeria(2014) 36 11 % 
Sekaran etal30  India(2012) 52 44.2% 
Rajagopal etal53  India(2015) 60 26.7% 
Aditi etal54  India(2015) 58 27.6% 
Gupta etal55  India(2017) 110 24.5% 
     
Current  study  India (2017) 72 11.1% 
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Table 14.HER 2 expression comparisons with age and gender 
                Gender                      Age   
Study     Male Female P 
value 
Younger Older P 
value 
       
Shan L44 109/1104(9.9%) 34/359(9.5%) 0.333 63/780(8.1%) 80/683(11.7%) 0.12 
Laboissiere49 7/64 (10.9%) 6/60 (10%) 0.865 9/82(10.9%) 4/42(9.5%) 0.865 
Fan56 73/713(10.3%) 18/244(7.4%) 0.001 66/682(9.7%) 25/295(8.5%) 0.418 
Current study 7/49(14.2%) 1/23(4.3%) 0.422 3/26(11.5%) 5/46(10.9%) 1 
Aditi54 12/43(27.9%) 4/15(26.7%) 0.103 9/36(25%)  7/22(31.8%) 0.781 
Gupta55 23/77(29.9%) 4/33(12.1%) 0.116 12/64(18.8%) 15/46(32.6%) 0.269 
Rajagopal53 11/36(30.56%) 5/24(20.8%) 0.056 * * * 
Sekaran30 16/34(47%) 7/18 (46.7%) 0.769 9/19(32.6%) 14/33(42.4%) 0.777 
* Not evaluated in the particular study 
 
 
TUMOR GEOGRAPHY 
Different studies have reported conflicting results regarding tumour location and Her2 
expression (see Table 15). Many authors and the current study showed no significant 
association between Her2 positivity and tumor topography. However the GERCOR study 
and Matsusaka et al. reported a significant association of Her2 positivity with proximal 
tumours. Gastric carcinoma in the Indian population tends to arise predominantly in the 
antrum especially when associated with precancerous conditions especially Helicobacter 
pylori chronic infection, tobacco and various dietary factors (seeTable15). The tumors of 
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the current study were mainly distal gastric carcinoma (58 cases out of 72). Our 
population is expected to have a lower HER 2 positivity rates.  HER 2 expression did not 
show any association with the location along the gastric curvatures in our study. For 
further detailed comparison between similar studies global population and Indian 
population (seeTable15 and 16). 
Table 15.HER 2 expression comparisons with Tumor geography 
Study Location  P value 
Proximal Middle Distal 
    
 
GERCOR etal57 21/105(20%) 6/571(10.5%) 5/56(8.9%) 0.017 
Laboissiere etal49 3/24(12.5%) * 10/100(10%) 0.720 
Hadi etal50 1/14(7.1%) * 6/37(16.2%) 0.575 
Current study 3/9(33.3%) 0/3(0%) 5/58(8.6%) 0.173 
Gupta etal55 17/56(30.3%) * 9/47(19.1%) 0.548 
Sekaran etal30 4/10(40%) * 9/47(19.1%) 1 
* Not evaluated in the particular study 
 
Table 16.HER 2 expression comparisons with gastric curvature 
Study Location P value 
Lesser Greater Circumferential 
     
Matsusaka etal45 121/550(22.1%) 48/202(23.8%) 60/332(18.1%) 0.395 
Indian studies53-55 * * * * 
Current study 3/21(14.2%) 0/5(0%) 5/46(10.9%) 0.86 
* Not evaluated in the particular study 
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HER 2 AND HISTOLOGICAL CLASSIFICATIONS 
A significant correlation between Lauren’s intestinal sub type and HER2 positivity has 
reported in most global and some Indian studies (see Table.17 and18).  For this reason, it 
recommended that, when dealing with a mixed adenocarcinoma (WHO 2010), areas 
showing an intestinal morphology should selected for HER2 scoring. Our data reinforce 
the fact that HER 2 positivity mixed adenocarcinoma with tumour heterogeneity is 
selectively expressed only in differentiated glandular areas. Laurens classified tumours 
into intestinal and diffuse in 1965. After that many people modified this classification by 
adding mixed and indeterminate types. We used the original classification with an 
addition of the general type.  We compared HER 2 expression with the latest WHO 
classification and found a statistically significant expression in mixed adenocarcinoma 
(p= 0.009%).  WHO 2010 classification is a relatively recent classification, and previous 
authors have not compared HER 2 expression with this classification system. For the 
detailed comparison between similar studies in the global and Indian population (see 
table17and 18). 
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Table 17.HER 2 comparisons with WHO (2010) classification 
Study WHO 2010 classification  P 
value 
Tubular pap PCC SCC Mixed Muc Others 
Current 
study  
3/25(12%) 0/0(0%) 0/27(0%) 0/6(0%) 5/12(41.6%) 0/1(0%) 0/1(0%) 0.009 
Grabsch 
etal58 
13/163(7.9%) 7/38(18.4%) 0/112(0%) * 2/34(5.9%) 2/7(28.5%) 0.017 
* Not evaluated in the particular study PCC –Poorly cohesive carcinoma, SCC -Signet ring cell carcinoma, PAP- papillary 
 
Table 18.HER 2 comparisons with Laurens classification 
Study Laurens  classification P value 
Intestinal Diffuse Mixed 
    
 
GERCOR57 23/107(21.5%) 3/56(5.3%) 6/55(10.9%) 0.002 
Shan etal44 109/650(16.8%) 13/564(2.3%) 21/249(8.4%) 0.001 
Fan etal56 84/568(8.4%) 7/389(1.8%) * 0.001 
Laboissiere etal49 11/61(18%) 0/21(0%) 2/33(6.1%) 0.048 
Hadi etal50 7/54(13%) 1/11(9.1%) 4/20(25%) 0.567 
Current study 4/26(15.4%) 4/44(9.1%) * 0.572 
Adithi etal54 15/43(34.8%) 1/15(6.7%) * 0.045 
Rajagopal etal53 16/49(32.7%) 0/11(0%) * 0.000 
Guptaetal55 21/57(36.8%) 5/47(10.6%) * 0.005 
Sekaranetal30 13/25(52%) 10/27(37%) * 0.4 
* Not evaluated in the particular study 
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TUMOR GRADE 
We found a higher rate of HER2 positivity in moderately and poorly differentiated types 
of intestinal adenocarcinoma. This finding is similar to those of the GERCOR study and 
that by Sekaran an et al. in which HER2 positive cases were moderately differentiated 
type adenocarcinoma in 65 % and 53 % respectively. Well, differentiated tumours in 
most of the studies had a meager rate of HER2 positivity. For further detailed comparison 
between similar research in the global and Indian population (seeTable19) 
 
Table 19.HER 2 comparison with Tumor grade 
Study Tumor grade  P value 
GradeI GradeII Grade III 
    
 
GERCOR etal57 3/92(3.3%) 21/55(38.1%) 8/71(11.3%) 0.001 
Shan etal44 4/25(16%) 74/369(20.1%) 65/1069(6.1%) 0.001 
Fan etal56 * 57/324(17.6%) 34/633(5.4%) 0.001 
Laboissiere etal49 4/13(30.8%) 7/45(15.6%) 2/66(3%) 0.04 
Hadietal50 0/4(0%) 9/50(18%) 3/31(9.7%) 0.272 
Current study 0/0(0%) 5/29(17.2%) 3/42(7.1%) 0.34 
Adithi etal54 * 12/24(50%) 3/13(23%) 0.111 
Gupta etal55 * 21/48(43.75%) 0/9(0%) 0.01 
Rajagopal etal53 * 16/40(40%) 0/11(0%) 0.01 
Sekaran etal30 * 10/19(52.6%) 13/33(39.4%) 0.396 
* Not evaluated in the particular study 
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LYMPHOVASCULAR INVASION AND PERINEURAL INVASION 
Table 20.HER 2 comparisons with LVI and PI 
 LVI  PI  
Study Present Absent P value Present Absent P value 
Laboissiere etal49 13/94(18.3%) 0/30(0%) 0.031 * * * 
Garbish etal58 15/199(7.5%) 9/219(4.1%) 0.133 * * * 
Current study 6/28(21.4%) 2/44(4.5%) 0.049 3/44(6.8%) 5/28(17.9%) 0.248 
Adithi etal54 * * * * * * 
Gupta etal55 5/30(16.7%) 1/8(12.5%) 0.89 5/27(18.5%) 1/13(7.7%) 0.66 
* Not evaluated in the particular study. LVI -Lympho vascular invasion, PI – Perineural invasion.  
 
 
DEPTH OF INVASION 
Table 21.HER 2 comparisons Depth of invasion 
Study   Depth of invasion 
           pT1 pT2 pT3           pT4 P 
value 
 PT1a PT1b   pT4a PT4b  
Matsusaka45 12/32(37.5%) 19/76(25%) 85/299(28.4%) 119/720(16.5%) 55/256(21.5%) 0.5 
Shan 44 16/206(7.8%) 23/147(15.6%) 102/1074(9.5%) 2/36(5.6%) 0.053 
Hadi50 0/0(0%) 4/14(28.6%) 5/45(11.1%) 3/26(11.5%) 0.499 
Laboissiere49 0/17(0%) 3/32(9.3%) 10/69(14.5%) 0/6(0%) 0.21 
Current study 0/3(0%)   0/2(0%)    2/7(28.6%) 5/22(22.7%) 1/38(2.6%) 0/0(0%) 0.248 
Gupta l55 0/4(0%) 1/5(20%) 3/23(13%) 2/8(25%) 0.598 
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REGIONAL LYMPH NODE METASTASIS 
Table 22.HER 2 comparisons in Regional lymph node metastasis 
Study                                      Regional  lymph node metastasis 
     N3 P 
value 
 N0 N1 N2 N3a N3b  
Matsusaka45 23/180(12.7%) 33/140(23.6%) 49/227(21.6%) 65/264(24.6%) 26/188(13.8%) 0.70 
Shan44 39/411(9.5%) 27/235(11.5%) 20/306(6.5%)             57/511(11.2%) 
              1/15(6.7%) 
              3/25(12%) 
0.074 
Laboissiere49 2/39(5.1%) 2/46(4.3%) 3/24(12.5%) 0.453 
Hadi50 3/21(14.3%) 2/11(18.2%) 4/25(16%) 0.724 
Current study 1/12(8.3%) 1/14(7.1%) 2/16(12.5%) 4/23(17.4%) 0/7(0%) 0.859 
Indian studies53-55   * 
 
* * * * * 
* Not evaluated in the particular study 
 
DISTANT METASTASIS 
Table 23.HER 2 comparison distant metastasis 
Study Distant metastasis  P value 
 M0 M1   
Shan etal44 140/1429(9.8%) 3/34(8.8%)  0.571 
Fan etal56 114/935(12.2%) 8/22(36.3%)  0.001 
Laboissiere etal49 13/12(10.7%) 0/3(0%) 
 
0.548 
Current study 8/71(11.3%) 0/1(0%) 
 
1 
Indian studies53-55 * *  * 
* Not evaluated in the particular study 
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PRECANCEROUS CONDITION 
In our study, among the 8HER 2 positive cases, 1 case showed active H pylori infection 
and in one case the adjacent mucosa exhibited dysplasia. So in our study there was no 
significant correlation between H. pylori and HER2 over-expression. After extensive 
search of the literature, we found only one study on HER expression in which 
precancerous conditions were evaluated (see Table 24).  
Table 24.HER 2expression-comparison with precancerous conditions 
Study Non identified H.pylori Gastritis  Intestinal metaplasia Dysplasia P value 
      
Current study  6/53(11.3%) 1/11(9.1%) 0/5(0%) 1/3(33.3%) 0.443 
      
Gharsalli etal51 4/30(13.3%) 2/13(15.4%) 2/18(11.1%)                    * 0.567 
* Not evaluated in the particular study 
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MATCHED BIOPSY WITH RESECTION AND TUMOR 
HETEROGENEITY 
There are very few studies comparing HER 2 expression in matched mucosal biopsies 
and resection specimens. The prevalence of HER 2 positive cases among resections and 
biopsies in the current study are 9.72% and 8.3% respectively.  The concordance rate of 
IHC in matching biopsy and surgical specimens is described in the Table 25. When   IHC 
considered as the gold standard, the positive predictive value of biopsies in predicting the 
final HER2 status was 65%. The NPV was   98 %.  Among the 8 HER2 positive cases, 
biopsies identiﬁed 6, and there were two false negative cases.  Therefore, 2 (25%) 
patients by biopsy ﬁndings could not have taken advantage of target therapy with 
Trastuzumab. In Table 26, we summarized the IHC results of the four concordant HER2 
positives and the four discordant cases, and we evaluated the homogeneity of IHC 
staining.  The false negative cases can be explained by the heterogeneous expression of 
the receptor and by the small number and size of biopsy specimens.  In our study, out of 
the 8 HER 2 3+ positive cases, 3 cases received neoadjuvant chemotherapy. 3 cases were   
HER 2 negative in resections and HER 2 positive in the biopsy. We found that the HER 2 
scores are modiﬁed by NACT on surgical specimens. Because of this reason, surgical 
specimens after NACT may-not be reliable for HER2 analysis, possibly because of the 
absence of residual tumour cells,   technical failure and negative shifts. Previous literature 
has shown that   HER2 positive tumour cells have been proven to have higher chemo 
sensitivity than HER2 negative cells, leading to the difficulty of HER2 detection in 
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tumours with high pathological responses after NACT(59).   All our concordant cases 
showed a homogeneous pattern of IHC staining, both in surgical and biopsy specimens.  
The discordance between the HER 2 positivity between resection blocks and biopsies can 
explain by pre analytical errors, the effect of neoadjuvant chemotherapy and Tumor 
heterogeneity (see Table 26). Recent studies by GERCOR et al. and   PIRRELLI et al. on 
matched resections and mucosal biopsies to compare HER2 expression scores found a 
concordance rate similar to our study, mostly due to intratumoral HER2 heterogeneity. 
Protein expression heterogeneity by IHC usually referred to as variability in 
immunohistochemical intensity and extension of HER2-positive areas. Intratumoral 
HER2 heterogeneity significantly impacts sample selection for HER2 testing in gastric 
carcinoma.   Many authors have demonstratedHER2 expression heterogeneity.   Whole 
tissue sections obtained from resected primary gastric tumours adequately represent 
multiple different subclonal cancer population cells which will avoid false negative 
staining by HER 2,   especially important in mixed adenocarcinoma variant that shows 
diverse clones of cancer cell populations. For Diagnostic endoscopic biopsies, a 
recommendation is an adequate, viable number of representative tumour fragments 
(ideally 6–8) and, consideration needs to given to performing HER2 testing on all 
available specimens when a negative result found on an endoscopic tumour biopsy(60). 
Most studies show a higher HER 2 positivity in biopsies compared to surgical specimens 
(see Table 27). This higher rate could be because of better fixation of tissue and minimal 
cold ischemic time in small biopsies when compared with resection specimen. But there 
is some limitation to this hypothesis since most studies are not using the same patient's 
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biopsy and resection for the comparison. When we compared matched biopsy and 
resection specimens we got a HER 2 positivity that was similar in biopsy and resection 
specimens: 8.33% and 9.72% respectively.  Analogous to the results of the GERCOR 
study (see Table 25 and 27). Literature also says that HER 2 positivity is more common 
in GEJ tumours when compared to other gastric carcinoma (see Table 27). The facts that 
our study was limited to gastric carcinoma tumours alone and most of the tumours were a 
poorly differentiated tumour and located in the antrum could explain our low prevalence 
of 11.1%. 
Table 25.HER2 Positivity Concordance rate, PPV, NPV 
Study  Biopsy Excision Concordance  rate PPV NPV 
GERCOR57  14.7% 13.3% 94% * * 
Pirelli etal61  11.5% * 98% 71.4% 94.4% 
Grillo etal62  * * 80% 78.6% 80% 
Lee etal63  31.2% 8.8 74.1% * * 
Wang etal64  10.1% 11.17 96.1% * * 
Current study   9.72% 8.3% 95.833 62.5% 98% 
* Not evaluated in the particular study  
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Table 26.HER2 Matched biopsy and resection Discordance and concordance 
 
Cases scenarios 
HER2 
positive 
biopsy 
 
HER2 
positive 
Resection 
DISCUSSION 
    
    
    
Case: (15, 35 ,59,60) 3+ 3+ 1. Homogeneous staining  
    
    
Case 62 3+ 0 1. Pre analytical errors in staining. 
2. Effect of neoadjuvant chemotherapy.  
3. Tumour heterogeneity. 
Case 68 3+ 0 
   
   
   
    
Case 5  0 3+ 1. Pre- analytical errors in staining. 
2. Tumour heterogeneity 
3. Inadequate sampling  
Case 64 0 3+ 
   
 
 
Table 27.HER 2 Comparison between biopsy with resection and gastric carcinoma with GEJC 
Study Biopsy Resection Study GEJC GC  
 Matched pairs    
GERCOR57 13.3% 14.7% Gravalo s etal29 25% 9.5% 
Current study 8.3% 9.72% Tanneretal65 24% 12% 
Wang etal64 10.1% 11.17% Shanetal44 32% 18% 
 Non matched pairs Lordicketal66 32% 18% 
   Rajagopaletal53 45.5% 22.2% 
Lee etal63 31.2% 8.8% Current study * 11.1% 
Aditietal54 34.1% 11.8%    
*Not evaluated, GC –Gastric carcinoma, GEJC – Gastro esophageal junction carcinoma. 
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14/72patients received Neoadjuvant chemotherapy (NAC) and in that 3/14 cases showed 
HER 2 positivity.  In the non-NAC study group   4/5 (80%) HER 2 positive cases showed 
concordance between biopsy and resection.  1/5 (20%) cases showed discordance with a 
positive shift (resection HER 2 positive and biopsy negative). In the NAC study group,   
3/3 (100%) HER 2 positive cases showed discordance with 2/3(75 %) showing a negative 
shift (resection HER 2 negative and biopsy positive) and 1/3 (25%) a positive shift.  3/5 
(60%) of treated patients showed tumour heterogeneity with a mixed histological type, 
and the remaining 2(40%) cases showed homogeneous staining pattern in tubular 
histological type. Our results match with those of the GERCOR study which evaluated 
two independent cohorts of NAC and none- NAC patients.  For detailed analysis and 
comparison with our study group see (figure 34). 
Some authors have also reported extensive cytoplasmic background staining of the 
gastric foveolar layer and foci of intestinal metaplasia/dysplasia49, as seen in our study, 
which suggests an intrinsic clonal characteristic rather than a methodological problem . In 
fact, HER2 staining of dysplastic epithelium has been correlated to gene amplification by 
ISH although there were no difficulties in distinguishing HER2-positive neoplastic cells 
from those areas, we stress that the staining of the latter must not be considered when 
scoring HER2 expression. 
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Figure34.Comparison between GERCOR study and Current study between matched biopsy and resection 
cases and the proportions of the concordance and discordance cases * NAC-Neoadjuvant chemotherapy. 
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Figure 35. Scenario1. Both biopsy and resection show HER 2(3+) and heterogeneity staining in biopsy as well 
as in resection with histo morphologically similar area (Case35) 
 
Figure 36.Scenario 2 Resection show 3+ and heterogeneity staining in mixed adeno carcinoma, Selective 
staining in neoplastic glandular areas. HER 0 in mucinous and poorly cohesive areas (Case 60). 
 
 
102 
 
 
Figure 37.Scenario 3 both biopsy and resection show tubular/intestinal type staining with homogenous 
staining (Case 15 and 59) 
 
 
Figure 38.Scenario 4 both biopsy and resection show tubular/intestinal type with Biopsy HER 2 0, and 
resection HER 3+ (Case 5 and 64) 
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Figure 39.Unusual staining pattern. A-Adjacent normal gastric foveolar epithelium,   B- Cytoplasmic and 
nuclear staining, C-smudgy staining, and D- Very rare scenario staining signet ring cells. 
 
FUTURE DIRECTIONS 
HER 2 testing kits have been available in the market from 1996 onwards and have been 
steadily increased in number over these 15 years. The accuracy and reproducibility of 
these assays has also improved from time to time. So the next question is whether we 
should continue to focus our efforts on improving existing HER2 testing methodologies 
or  focus on other potentially better tests for selecting patients who would benefit from 
HER2-directed therapies(67).Serum tests may simplify the determination of HER2 status 
testing if a reliable test can develop. Potential candidates for such a test are soluble HER2 
(sHER2) extracellular domain (ECD) And HER2 in circulating tumor cells (CTCs).  
Levels of sHER2 ECD can be accurately quantified in serum using an ELISA, which is 
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relatively quick and straightforward compared with IHC and FISH.  HER2-positive CTCs 
do not necessarily reflect the HER2 status of a primary tumor but may indicate the status 
of potential metastatic deposits.  HER2 gene amplification and mRNA over expression 
are intrinsically linked; therefore the utility of quantitative real-time polymerase chain 
reaction (RT-PCR) has been assessed as a potential alternative to IHC and FISH.  The 
simplicity and accuracy of HER2 testing increased with the current quantitative RT-PCR 
testing with advantages over current methods such as it is a purely quantitative 
measurement.  Interpretation of data need not need a trained person to interpret. It's also 
not subject to intraobserver variability and can be standardized, automated and performed 
on small samples. Another mRNA technique has recently been reported, using automated 
direct quantification of HER2 mRNA by in situ hybridization.  All these advanced 
techniques have sidesteps problems that can lead to equivocal results in RT-PCR, such as 
tumor heterogeneity or mixing of a tumor and non-tumor cells during sample preparation. 
However utilizing this molecular tumor signature may lead to improvements in diagnosis, 
recurrence prediction, and individualized treatment strategies. The heterogeneity issue 
has raised questions on whether tumors with< 10% positively stained cells would respond 
toHER2 targeted therapy, despite classification as HER2 negative with current scoring 
criteria. In tumors in which strong complete/basolateral or lateral membrane staining seen 
in< 10% of the cells, IHC staining should be repeated on a different paraffin block 
section, and if still inconclusive, an ISH test should be performed to determine HER2 
gene amplification and final HER2 status(68). 
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LIMITATION 
1.    Patient classified as equivocal for HER2 positivity require additional testing (FISH, 
SISH) to confirm or deny HER2 positivity. Due to cost constraints, this was not planned 
in our study. Doing FISH would have been helpful for the better understanding of the 
relation between HER2 heterogeneity and identifying the false positive and negative 
cases. FISH is the gold standard test for HER 2 amplification assessment. 
2.    All efforts were taken to minimize the pre analytical errors, but due to logistic 
reasons, the time taken from the retrieval of gastric tissue to fixing it in formalin was 
variable and may potentially affect the staining pattern of tumor cells. 
3.    Most of the patients in our study were from Bangladesh and West Bengal. Our 
results, therefore, may not reflect the actual prevalence of the condition in the entire 
Indian population. 
4.    Our study was a prospective study, so because of the time constraint, follow up of 
HER 2 positive gastric carcinoma patients were for a limited duration.  
5.    The number of patients enrolled in this study compared to other international studies 
is relatively small. Larger numbers are needed to substantiate the findings of this study. 
6. We assumed that all resection cases with no glandular differentiation and HER 2 IHC 0 
and IHC 1+ would be uniformly HER 2negative. Only HER2 positive 3+ cases we 
reassessed for HER 2intratumoralheterogeneity. There is a chance that intratumoral 
heterogeneity may also have been present in other HER2 negative cases. 
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CONCLUSION 
 
 Our study found HER2 over expressionin11.11% of gastric cancers, similar to 
most studies in India and the rest of the world.  
 HER 2 positivity (3+) was most common in the mixed, intestinal type and 
moderately differentiated carcinomas. 
 We found a statistically significant correlation betweenHER2 over expression and 
mixed adenocarcinoma (WHO classification) and the presence of lymph vascular 
invasion in gastric cancers, suggesting that these cases may benefit from targeted 
therapy using Trastuzumab Diffuse type of gastric cancers not expressing HER2 
need to be studied further, to confirm any existing geographic variation. 
 In the era of automated techniques and expertise we should pay more attention to 
prevent pre analytical errors in HER 2 staining by using standard operating 
protocols in each lab. Importance of the cold ischemic time needs to be further 
analyzed in gastric resection specimens in future studies. 
 Though  Trastuzumab is approved for advanced gastric and GEJ cancers, the role 
of  Trastuzumab in adjuvant / neo-adjuvant setting in early stages needs to be 
evaluated, including the use of newer agents like Pertuzumab and Bevacizumab, 
especially in young patients. 
 Concordance of HER expression between gastrectomies and biopsies in our study 
was 95.3 %. . The differences between biopsy and resection specimen HER2 
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expression could be explained by intratumoral heterogeneity and by a decrease in 
HER2 expression in surgical sections after NAC in patients responding to 
treatment, possibly due to a higher chemo sensitivity of HER2-positive clones. 
 The NPV for HER2 expression in endoscopic biopsies was very high, but the PPV 
was rather unsatisfactory. This is mainly due to the intrinsic heterogeneity of 
HER2 expression in gastric carcinoma. A larger number of biopsies and a second 
set of biopsies to study HER2 expression could be useful in selected inoperable 
cases, such as those of intestinal type or Mixed type in which a greater probability 
of achieving a positive result is expected.  
 The current study demonstrated significant intratumoral heterogeneity in HER2 
protein over expression even without morphological heterogeneity.  
 Intratumoral   heterogeneity is likely to affect the accuracy of HER2 interpretation 
by a pathologist and is likely to be the main reason of discordance between   
endoscopic biopsies versus resection tumor specimens.  
 Resection tumor specimens have higher positive rates of HER2 protein over 
expression, probably because of a larger sample volume.  
 The clinical signiﬁcance of intratumoral heterogeneity and its impact on targeted 
therapy outcome in gastric cancer requires further studies. 
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Slandered operating protocol for HER 2 IHC staining 
Details of the HER 2 IHC staining is as follows: 
Ventana (Pathway) anti HER 2/neu (4B5) Rabbit Monoclonal Primary Antibody 
procedure - MILD- 32 CC1 PROTOCOL 
PATHWAY HER2 (4B5) is a rabbit monoclonal antibody, which binds to HER2 in 
paraffin embedded tissue sections. The specific antibody can be localized by either a 
biotin conjugated secondary antibody formulation that recognizes rabbit 
immunoglobulins followed by the addition of a streptavidin-horseradish peroxides (HRP) 
conjugate a secondary antibody-HRP conjugate (Ultra view Universal DAB detection 
kit). The specific antibody-enzyme complex is then visualized with a precipitating 
enzyme reaction product. Each step is incubated at a precise time and temperature. At the 
end of each incubation step, the Ventana automated slide stainer washes the sections to 
stop the reaction and to remove unbound material that would hinder the desired reaction 
in subsequent steps. It also applies Liquid Coverslip™, which minimizes evaporation of 
the aqueous reagents from thespecimen slide. Clinical cases should be evaluated within 
the context of the performance of appropriate controls. Ventana recommends the 
inclusion of a positive tissue control fixedand processed in the same manner as the patient 
specimen (for example, positive breast carcinoma or uterus). 
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ANNEXURES -7 
Important scoring system  
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ANNEXURES -8 
 
                               WHO 2010 Gastric adenocarcinoma classification 
8260 Papillary adenocarcinoma: composed of well-differentiated Exophytic carcinoma 
with elongated finger-like processes lined by cylindrical or cuboidal cells supported by 
fibrovascular connective tissue cores. The cells tend to maintain their polarity. Some 
tumours show tubular (papilla tubular) differentiation. Rarely, micropapillary architecture 
is present. The degree of cellular atypia and mitotic index vary; there may be severe 
nuclear atypia. The invading edge of the tumour is usually sharply demarcated; the 
tumour may be infiltrated by acute and chronic inflammatory cells. 
8211 Tubular adenocarcinoma:  composed of the predominance of tube-like epithelial 
structures. Tubular adenocarcinoma of the stomach is composed of dilated or slit-like and 
branching tubules of varying diameter. Acinar structures may also be present 
8480 Mucinous adenocarcinoma:  composed of malignant epithelium and extracellular 
mucinous pools. By convention, the tumour shows more than 50% extracellular mucin. 
Mucinous carcinomas may contain scattered signet-ring cells. 
8490 Signet ring cell carcinoma: Signet ring cell carcinoma is predominantly composed 
of signet-ring cells containing aclear droplet of cytoplasmic mucin displacing the nucleus. 
8490 Poorly cohesive carcinoma:Tumor cells infiltrate as isolated single cells or small 
aggregates. Signet ringastric carcinoma ell carcinoma is predominantly composed of 
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signet-ring cells containing aclear droplet of cytoplasmic mucin displacing the nucleus. 
Other variants ofpoorly cohesive carcinoma may resemble mononuclear inflammatory 
cells 
 
8255: Mixed adenocarcinoma: Mixed carcinomas display a mixture of discrete 
morphologically identifiable glandular (tubular/papillary) and signet-ring/poorly-
cohesive cellular histological components. Any discrete histological component should 
be reported; although the prognostic relevance of the proportion of each component has 
not been established, preliminary data suggest that any signet-ring/poorly cohesive 
cellular histological component is associated with a poor prognosis.Mixed carcinomas are 
clonal and phenotypic divergence has been attributed to the somatic mutation in the E-
cadherin gene (CDH1), which is restricted to the signet-ring/poorly-cohesive component. 
8560 Adenosquamous carcinoma:  Mixture of glandular and squamous neoplastic 
components; the squamous 
the component should comprise at least 25% of tumour volume. 
 
8512 Carcinoma with lymphoid stroma: This tumour, also reported as 
lymphoepithelioma-like carcinoma or medullary carcinoma, is characterized by poorly 
developed tubular structures associated with a prominent lymphoid infiltration of the 
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stroma. These tumours frequently affect the proximal stomach or gastric stump and are 
more common in males while > 80% are associated with infection with Epstein-Barr 
virus (EBV) 1. The role of EBV in carcinogenesis is debated but occurs at an early stage 
since EBV can be found in adjacent dysplasia. The prognosis for patients with these 
tumours is reportedly better than that for patients with typical gastric cancers. 
8214 Parietal cell carcinoma: composed of well to moderately differentiated tubular 
adenocarcinoma with very eosinophilic, finely granular cytoplasm. Immunohistochemical 
stains for anti mitochondrial antibody were strongly positive. 
 
8576 Hepatoid adenocarcinoma:Hepatoid adenocarcinoma of the stomach is composed 
of large polygonal eosinophilic hepatocyte-like neoplastic cells. α-Fetoprotein (AFP) can 
be detected in situ, but also in the serum. Bile and periodic acid-Schiff (PAS)- positive 
and diastase-resistant intracytoplasmiceosinophilic globules can be observed 3. Other rare 
AFP-producing carcinomas include well-differentiated papillary or tubular-type 
adenocarcinoma with clear cytoplasm and yolk-sac tumour-like carcinoma 
 
8070 Squamous cell carcinoma, NOS: A carcinoma arising from squamous epithelial 
cells, morphologically characterized by the proliferation of atypical, often pleomorphic 
squamous cells. Squamous cell carcinomas are graded as well, moderately, or poorly 
differentiated. Well, differentiated carcinomas are usually associated with keratin 
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production and the presence of intercellular bridges between adjacent cells.  Squamous 
cell carcinoma of the stomach is very rare 
8082 Lymphoepithelial carcinoma: Lymphoepithelioma-like carcinoma (LLC) is a 
rare and peculiar type of gastric carcinoma that is reported to be associated with latent 
Epstein-Barr virus (EBV) infection. Histopathologically, the carcinoma cell nests were 
surrounded by prominent lymphoid stroma. Sarcoid-like epithelioid granulomas were 
noted both in the tumourstroma and in the regional lymph node with metastasis.  
8510 Medullary carcinoma, NOS: 
8020 Undifferentiated carcinoma: High-grade carcinoma that cannot be further 
classified as adenocarcinoma, 
squamous cell carcinoma, or other recognized variants 
8246 Neuroendocrine carcinoma: A neuroendocrine carcinoma (NEC) is a poorly 
differentiated, high grade malignant neoplasm composed of small cells or large to 
intermediate cells, sometimes with organoid features resembling NET, diffusely 
expressing the general markers of neuroendocrine differentiation (diffuse expression of 
synaptophysin; faint or focal staining for chromogranin A), with marked nuclear atypia, 
multifocal necrosis and a high number of mitoses (> 20 per 10 HPF); high grade (G3) 
defined according to the proliferation fraction and histology. This definition refers to 
neoplasms previously classified as small cell carcinoma, large cell (neuro)endocrine 
carcinoma, or poorly differentiated (neuro)endocrine carcinoma 
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8013 Large cell neuroendocrine carcinoma: A usually aggressive carcinoma composed 
of large malignant cells which display neuroendocrine characteristics. It is characterized 
by the presence of high mitotic activity and necrotic changes.  
8041 Small cell neuroendocrine carcinoma: A neuroendocrine carcinoma composed of 
small malignant cells which histologically often resemble "oat cells". Clinically, this is 
often a rapidly growing cancer that spreads to distant sites early.  
8244 Mixed adenoneuroendocrine carcinoma: Mixed adenoneuroendocrine 
carcinomas (MANEC) have a phenotype that is morphologically recognizable as both 
gland-forming epithelial and neuroendocrine, and are defined as carcinomas since both 
components are malignant and should be graded. A component of squamous cell 
carcinoma is rare. Arbitrarily, at least 30% of either component should be identified to 
qualify for this definition. The identification in adenocarcinoma of scattered 
neuroendocrine cells by immune histochemistry does not qualify for this definition 
 
 
 
ANNEXURES -9 
 
Macroscopic - Bormann classification 
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The Type 1 Polypoid: Well circumscribed polypoidtumours. Polypoid carcinoma of the 
stomach is located in the antrum of the lesser curvature. This elevating solid mass shows 
focal superficial haemorrhage. 
Type 2 Fungating: Fungatingtumours with marked central infiltration and most of the 
time with a central ulceration. The most common type.  Lesser curvature of the antrum is 
the most common site.  
Type 3 Ulcerated: Ulcerated tumours with infiltrative margins. Ulcerated carcinoma of 
the stomach with infiltrative and heaped-up margins is present The lesser curvature near 
the body Polypoid (type 1), and ulcerated (type 3) types are commonly found in the 
greater curvature.  
Type 4 Infiltrating: Diffusely infiltrated tumours. Linitis plastic, diffusely infiltrating 
carcinoma of the stomach with thickening of gastric rugae involves the whole stomach 
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ANNEXURE-10 
Table 28. Tumor Regression Grade 
                                                       Tumor Regression Grade 
0 No viable cancer cells 0 (Complete response) 
1 Single cells or small groups of cancer cells (Moderate response) 
2   Residual cancer outgrown by fibrosis.  (Minimal response) 
3 extensive residual cancer (Poor response) 
 
 
 
Table 29.HER 2 standard operating methods 
Assay type Trade name Manufacturer 
Date of FDA 
approval 
    
Semi-quantitative 
IHC HercepTest™ DAKO September 1998 
IHC PATHWAY 
Ventana Medical Systems 
Inc November 2000 
IHC InSite Biogenex Laboratories Inc December 2004 
Semi-quantitative 
IHC Bond Oracle™ Leica Biosystems April 2012 
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ANNEXURES -11 
WHO common histological type 
 
Figure 40.Common WHO subtype A-Tubular, B-papillary, C-Mucinous, D-Signet ring cell 
 
 
 
 
Figure 41.Diffuse type carcinoma subtype. A&B – Poorly cohesive carcinoma. C&D- Signet ring cell 
carcinoma 
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ANNEXURES -11 
 
Table 30.DATA SHEETS 
NO AGEBAR AGE SEX PLACE SURG LOCATION CURVE SIZE    Bormann        LRN M.LRN WHO PM DM 
1 <50 yrs 66 male W.B D.SUBTOTAL D.ANTRUM CIRCUMF 33 TYPE III DIFFUSE D PCC NOT INV  NOT INV 
2 <50 yrs 62 male W.B TOTAL FUNDUS CIRCUMF 47 TYPE III DIFFUSE D MIXED NOT INV  NOT INV 
3 >50 yrs 23 female W.B D.SUBTOTAL D.ANTRUM CIRCUMF 50 TYPE IV DIFFUSE D MIXED NOT INV  NOT INV 
4 <50 yrs 53 female T.N D.SUBTOTAL D.ANTRUM CIRCUMF 60 TYPE IV DIFFUSE D PCC NOT INV INV 
5 <50 yrs 55 male W.B D.SUBTOTAL D.ANTRUM LESSER 20 TYPE III INTESTINAL DND MIXED NOT INV  NOT INV 
6 >50 yrs 32 female T.N TOTAL D.ANTRUM CIRCUMF 120 TYPE IV DIFFUSE D SCC  INV INV 
7 <50 yrs 54 male B.DESH TOTAL FUNDUS LESSER 70 TYPE III INTESTINAL PND TUBULAR NOT INV  NOT INV 
8 <50 yrs 55 female W.B D.SUBTOTAL D.ANTRUM CIRCUMF 50 TYPE IV DIFFUSE D PCC NOT INV  NOT INV 
9 <50 yrs 68 male W.B TOTAL BODY LESSER 80 TYPE II INTESTINAL PND TUBULAR NOT INV  NOT INV 
10 <50 yrs 73 male J.KHAND TOTAL D.ANTRUM LESSER 60 TYPE II DIFFUSE D PCC NOT INV  NOT INV 
11 >50 yrs 35 female B.DESH TOTAL D.ANTRUM CIRCUMF 10 TYPE II DIFFUSE D MIXED NOT INV  NOT INV 
12 <50 yrs 51 male B.DESH D.SUBTOTAL D.ANTRUM LESSER 65 TYPE II INTESTINAL DND TUBULAR NOT INV  NOT INV 
13 >50 yrs 43 male T.N D.SUBTOTAL D.ANTRUM LESSER 30 TYPE III INTESTINAL DND TUBULAR NOT INV  NOT INV 
14 <50 yrs 61 female W.B D.SUBTOTAL D.ANTRUM CIRCUMF 40 TYPE IV INTESTINAL DND TUBULAR NOT INV  NOT INV 
15 <50 yrs 57 male B.DESH TOTAL FUNDUS LESSER 80 TYPE II INTESTINAL PND TUBULAR NOT INV  NOT INV 
16 >50 yrs 41 male B.DESH D.SUBTOTAL BODY LESSER 110 TYPE II DIFFUSE D PCC NOT INV  NOT INV 
17 <50 yrs 58 male T.N D.SUBTOTAL D.ANTRUM GREATER 70 TYPE II DIFFUSE D PCC NOT INV  NOT INV 
18 >50 yrs 41 female J.KHAND D.SUBTOTAL D.ANTRUM CIRCUMF 80 TYPE IV DIFFUSE D SCC NOT INV  NOT INV 
19 >50 yrs 45 male W.B D.SUBTOTAL D.ANTRUM CIRCUMF 80 TYPE II INDETER D MUC NOT INV  NOT INV 
20 <50 yrs 59 female B.DESH D.SUBTOTAL D.ANTRUM CIRCUMF 50 TYPE II INTESTINAL DND TUBULAR NOT INV  NOT INV 
21 <50 yrs 57 male J.KHAND D.SUBTOTAL BODY CIRCUMF 80 TYPE II DIFFUSE D PCC NOT INV  NOT INV 
22 <50 yrs 60 male T.N D.SUBTOTAL D.ANTRUM CIRCUMF 50 TYPE III DIFFUSE D MIXED NOT INV  NOT INV 
23 <50 yrs 65 male W.B D.SUBTOTAL D.ANTRUM LESSER 15 TYPE III INTESTINAL DND TUBULAR NOT INV  NOT INV 
24 <50 yrs 62 male T.N D.SUBTOTAL D.ANTRUM LESSER 30 TYPE II INTESTINAL DND TUBULAR NOT INV  NOT INV 
25 >50 yrs 37 male W.B D.SUBTOTAL D.ANTRUM CIRCUMF 90 TYPE IV DIFFUSE D SCC NOT INV  NOT INV 
26 >50 yrs 46 male W.B D.SUBTOTAL D.ANTRUM CIRCUMF 65 TYPE II DIFFUSE D PCC NOT INV  NOT INV 
27 <50 yrs 54 male W.B D.SUBTOTAL D.ANTRUM CIRCUMF 25 TYPE III DIFFUSE D PCC NOT INV  NOT INV 
28 <50 yrs 53 male B.DESH D.SUBTOTAL D.ANTRUM LESSER 70 TYPE IV DIFFUSE D SCC NOT INV  NOT INV 
29 >50 yrs 29 female B.DESH D.SUBTOTAL D.ANTRUM GREATER 25 TYPE II DIFFUSE D PCC NOT INV INV 
30 >50 yrs 36 female J.KHAND D.SUBTOTAL D.ANTRUM CIRCUMF 40 TYPE II DIFFUSE D PCC NOT INV  NOT INV 
31 <50 yrs 69 female B.DESH D.SUBTOTAL D.ANTRUM CIRCUMF 60 TYPE IV DIFFUSE D PCC NOT INV INV 
32 <50 yrs 68 male T.N D.SUBTOTAL D.ANTRUM CIRCUMF 40 TYPE III INTESTINAL DND TUBULAR NOT INV  NOT INV 
33 >50 yrs 35 male W.B D.SUBTOTAL D.ANTRUM CIRCUMF 15 TYPE III DIFFUSE D PCC NOT INV  NOT INV 
34 <50 yrs 64 male W.B D.SUBTOTAL D.ANTRUM CIRCUMF 45 TYPE III INTESTINAL DND TUBULAR NOT INV  NOT INV 
35 >50 yrs 32 male W.B D.SUBTOTAL D.ANTRUM CIRCUMF 70 TYPE III DIFFUSE D MIXED NOT INV  NOT INV 
36 <50 yrs 51 female B.DESH D.SUBTOTAL D.ANTRUM CIRCUMF 40 TYPE IV DIFFUSE D PCC NOT INV  NOT INV 
37 <50 yrs 79 male B.DESH D.SUBTOTAL D.ANTRUM CIRCUMF 35 TYPE IV DIFFUSE D PCC NOT INV  NOT INV 
135 
 
38 <50 yrs 60 female J.KHAND TOTAL D.ANTRUM CIRCUMF 15 TYPE IV DIFFUSE D PCC NOT INV  NOT INV 
39 <50 yrs 72 female T.N D.SUBTOTAL D.ANTRUM CIRCUMF 90 TYPE II DIFFUSE D PCC NOT INV  NOT INV 
40 <50 yrs 67 male B.DESH D.SUBTOTAL D.ANTRUM LESSER 60 TYPE III INTESTINAL DND TUBULAR NOT INV  NOT INV 
41 <50 yrs 61 female B.DESH TOTAL FUNDUS LESSER 60 TYPE IV DIFFUSE D PCC NOT INV  NOT INV 
42 <50 yrs 57 male NEPAL D.SUBTOTAL D.ANTRUM LESSER 45 TYPE III INTESTINAL DND TUBULAR NOT INV  NOT INV 
43 <50 yrs 60 male B.DESH D.SUBTOTAL D.ANTRUM GREATER 11 TYPE III INTESTINAL PND TUBULAR NOT INV  NOT INV 
44 <50 yrs 51 male T.N D.SUBTOTAL D.ANTRUM CIRCUMF 45 TYPE II DIFFUSE D MIXED NOT INV  NOT INV 
45 >50 yrs 42 male T.N TOTAL D.ANTRUM LESSER 80 TYPE III INTESTINAL DND TUBULAR NOT INV  NOT INV 
46 >50 yrs 48 female B.DESH TOTAL WHOLE CIRCUMF 20 TYPE IV DIFFUSE D SCC NOT INV  NOT INV 
47 <50 yrs 54 female ODISSA D.SUBTOTAL D.ANTRUM CIRCUMF 10 TYPE III INTESTINAL DND TUBULAR NOT INV  NOT INV 
48 <50 yrs 58 female T.N TOTAL FUNDUS CIRCUMF 100 TYPE IV DIFFUSE D SCC  INV  NOT INV 
49 <50 yrs 51 male B.DESH TOTAL WHOLE CIRCUMF 50 TYPE III DIFFUSE D MIXED NOT INV INV 
50 <50 yrs 82 male T.N D.SUBTOTAL D.ANTRUM CIRCUMF 50 TYPE II INTESTINAL DND TUBULAR NOT INV  NOT INV 
51 <50 yrs 70 male W.B D.SUBTOTAL D.ANTRUM GREATER 35 TYPE III DIFFUSE D PCC NOT INV  NOT INV 
52 <50 yrs 70 male T.N TOTAL FUNDUS LESSER 35 TYPE III INTESTINAL PND TUBULAR NOT INV  NOT INV 
53 >50 yrs 46 male B.DESH D.SUBTOTAL D.ANTRUM CIRCUMF 12 TYPE III INTESTINAL DND TUBULAR NOT INV  NOT INV 
54 <50 yrs 59 male J.KHAND D.SUBTOTAL D.ANTRUM CIRCUMF 50 TYPE III DIFFUSE D PCC NOT INV  NOT INV 
55 >50 yrs 45 male W.B D.SUBTOTAL D.ANTRUM LESSER 7 TYPE III INTESTINAL DND TUBULAR NOT INV  NOT INV 
56 <50 yrs 59 female W.B D.SUBTOTAL D.ANTRUM CIRCUMF 30 TYPE III DIFFUSE D PCC NOT INV  NOT INV 
57 >50 yrs 48 male A.P D.SUBTOTAL D.ANTRUM CIRCUMF 60 TYPE III DIFFUSE D PCC NOT INV  NOT INV 
58 <50 yrs 60 male J.KHAND D.SUBTOTAL D.ANTRUM LESSER 25 TYPE III DIFFUSE D PCC NOT INV  NOT INV 
59 >50 yrs 35 female T.N D.SUBTOTAL D.ANTRUM CIRCUMF 70 TYPE II INTESTINAL DND TUBULAR NOT INV  NOT INV 
60 <50 yrs 66 male B.DESH D.SUBTOTAL D.ANTRUM CIRCUMF 30 TYPE IV DIFFUSE D MIXED NOT INV  NOT INV 
61 >50 yrs 49 male W.B D.SUBTOTAL D.ANTRUM CIRCUMF 25 TYPE III INDETER DND LYMPOID NOT INV  NOT INV 
62 <50 yrs 53 male W.B TOTAL FUNDUS CIRCUMF 60 TYPE III DIFFUSE D MIXED  INV INV 
63 <50 yrs 56 male W.B TOTAL FUNDUS LESSER 20 TYPE III INTESTINAL PND TUBULAR NOT INV  NOT INV 
64 >50 yrs 24 male T.N TOTAL FUNDUS LESSER 60 TYPE III DIFFUSE D MIXED NOT INV  NOT INV 
65 >50 yrs 44 male B.DESH D.SUBTOTAL D.ANTRUM CIRCUMF 60 TYPE IV DIFFUSE D PCC NOT INV  NOT INV 
66 <50 yrs 59 male W.B D.SUBTOTAL D.ANTRUM LESSER 35 TYPE III INTESTINAL DND TUBULAR NOT INV  NOT INV 
67 >50 yrs 39 female W.B D.SUBTOTAL D.ANTRUM GREATER 50 TYPE II INTESTINAL DND TUBULAR NOT INV  NOT INV 
68 <50 yrs 63 male B.DESH D.SUBTOTAL D.ANTRUM CIRCUMF 20 TYPE III INTESTINAL DND TUBULAR NOT INV  NOT INV 
69 >50 yrs 43 male W.B D.SUBTOTAL D.ANTRUM CIRCUMF 50 TYPE II DIFFUSE D MIXED NOT INV  NOT INV 
70 >50 yrs 49 female A.P D.SUBTOTAL D.ANTRUM CIRCUMF 80 TYPE IV DIFFUSE D PCC NOT INV  NOT INV 
71 <50 yrs 51 male T.N D.SUBTOTAL D.ANTRUM CIRCUMF 60 TYPE III DIFFUSE D PCC NOT INV  NOT INV 
72 >50 yrs 49 female A.P D.SUBTOTAL D.ANTRUM CIRCUMF 80 TYPE II DIFFUSE D PCC NOT INV  NOT INV 
 
 
 
 
 
     CONTD……… 
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NO DEPTH RLN MO STAGE PRECAN GRADE LVI PI NACT TMR RESP RSCORE BSCORE RSTAT BSTAT 
1 T3 N1 M0 IIB H.PYLORI III PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
2 T4a N2 M0 IIIA NON III PRESENT PRESENT YES 2 POOR 0 0 NEGATIVE NEGATIVE 
3 T4a N3a M0 IIIB NON II ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
4 T4a N3a M0 IIIB H.PYLORI III PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
5 T2 N0 M0 IB H.PYLORI II ABSENT ABSENT NO .   . 3 3 POSITIVE POSITIVE 
6 T4a N3a M0 IIIB NON III PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
7 T4a N1 M0 IIIA NON I ABSENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
8 T4a N2 M0 IIIA NON III ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
9 T4a N3a M1 IV NON II PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
10 T4a N3b M0 IIIC NON III PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
11 T4a N3a M0 IIIC NON II PRESENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
12 T3 N1 M0 IIB H.PYLORI II PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
13 T3 N0 M0 IIA NON II ABSENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
14 T4a N0 M0 IIB NON II ABSENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
15 T3 N3a M0 IIIB NON II PRESENT PRESENT NO .   . 3 3 POSITIVE POSITIVE 
16 T4a N3b M0 IIIC NON III ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
17 T4a N2 M0 IIIA NON III ABSENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
18 T4a N3b M0 IIIC NON III ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
19 T4a N3a M0 IIIB NON III ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
20 T4a N3a M0 IIIB H.PYLORI II ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
21 T4a N3a M0 IIIB NON III ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
22 T3 N3a M0 IIIB NON III ABSENT ABSENT NO .   . 1 1 NEGATIVE NEGATIVE 
23 T2 N1 M0 IIA IM II ABSENT ABSENT NO .   . 1 1 NEGATIVE NEGATIVE 
24 T4a N2 M0 IIIA H.PYLORI II ABSENT PRESENT NO .   . 1 1 NEGATIVE NEGATIVE 
25 T4a N3a M0 IIIB NON III ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
26 T3 N3a M0 IIIB H.PYLORI III ABSENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
27 T1a N1 M0 IB IM III PRESENT ABSENT YES 1 GOOD 0 0 NEGATIVE NEGATIVE 
28 T4a N3a M0 IIIB NON III ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
29 T4a N3b M0 IIIC NON III ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
30 T3 N3a M0 IIIB NON III PRESENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
31 T4a N2 M0 IIIA NON III PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
32 T4a N3a M0 IIIB NON II ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
33 T4a N1 M0 IIIA NON III ABSENT PRESENT YES 1 GOOD 0 0 NEGATIVE NEGATIVE 
34 T3 N0 M0 IIA NON II ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
35 T3 N3a M0 IIIB DYSPLASIA II PRESENT ABSENT NO .   . 3 3 POSITIVE POSITIVE 
36 T4a N2 M0 IIIA NON III PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
37 T4a N3a M0 IIIB NON III PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
38 T1a N0 M0 IIA NON III ABSENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
39 T4a N3a M0 IIIB NON III PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
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40 T4a N3a M0 IIIB NON II ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
41 T3 N0 M0 IIA NON III ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
42 T3 N1 M0 IIB DYSPLASIA II PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
43 T3 N0 M0 IIA NON II ABSENT PRESENT YES 1 POOR 0 0 NEGATIVE NEGATIVE 
44 T4a N3a M0 IIIB NON III PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
45 T4a N3b M0 IIIC NON II PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
46 T4a N1 M0 IIIA NON III ABSENT ABSENT YES 2 POOR 0 0 NEGATIVE NEGATIVE 
47 T1b N1 M0 IB IM II PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
48 T4a N1 M0 IIIA NON III PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
49 T4a N3b M0 IIIC NON III PRESENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
50 T2 N2 M0 IIB IM II ABSENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
51 T4a N2 M0 IIIA NON III ABSENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
52 T3 N2 M0 IIIA NON II ABSENT PRESENT YES 3 POOR 1 0 NEGATIVE NEGATIVE 
53 T3 N1 M0 IIB DYSPLASIA II ABSENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
54 T1a N1 M0 IIB NON III ABSENT ABSENT YES 1 GOOD 0 0 NEGATIVE NEGATIVE 
55 T2 N0 M0 IB NON II ABSENT ABSENT YES 1 GOOD 0 0 NEGATIVE NEGATIVE 
56 T1b N0 M0 IA NON III ABSENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
57 T3 N3b M0 IIIC H.PYLORI III PRESENT ABSENT YES 3 POOR 0 0 NEGATIVE NEGATIVE 
58 T3 N1 M0 IIB NON III ABSENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
59 T3 N3a M0 IIIB NON II PRESENT ABSENT NO .   . 3 3 POSITIVE POSITIVE 
60 T3 N3a M0 IIIB NON III PRESENT PRESENT NO .   . 3 3 POSITIVE POSITIVE 
61 T2 N0 M0 IB H.PYLORI II ABSENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
62 T4a N1 M0 IIIA NON III PRESENT PRESENT YES 2 POOR 3 0 POSITIVE NEGATIVE 
63 T3 N2 M0 IIIA H.PYLORI II ABSENT PRESENT YES 3 POOR 0 0 NEGATIVE NEGATIVE 
64 T3 N2 M0 IIIA NON III ABSENT ABSENT YES 3 POOR 3 0 POSITIVE NEGATIVE 
65 T4a N2 M0 IIIA NON III ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
66 T2 N0 M0 IB IM II ABSENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
67 T3 N0 M0 IIA NON II PRESENT ABSENT NO .   . 0 0 NEGATIVE NEGATIVE 
68 T2 N2 M0 IIB NON II PRESENT ABSENT YES 1 GOOD 0 3 NEGATIVE POSITIVE 
69 T4a N2 M0 IIIA NON III ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
70 T4a N2 M0 IIIA NON III ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
71 T3 N3a M0 IIIA H.PYLORI III ABSENT PRESENT YES 3 POOR 0 0 NEGATIVE NEGATIVE 
72 T4a N2 M0 IIIA NON III ABSENT PRESENT NO .   . 0 0 NEGATIVE NEGATIVE 
                
 
